🇬🇧 English 🇷🇴 Română 🇪🇸 Español soon 🇫🇷 Français soon 🇩🇪 Deutsch soon
Log in Register
e

Pfizer Inc (PFE.US) - analysis, score and valuation

Investește acum AD

Is it worth investing?

Pfizer Inc is a middle-of-the-road business, at a price that demands patience.

$28.12 +16.80% over 12 months Last updated: iun. 10, 2026

Pfizer Inc (PFE) is a company in the Drug Manufacturers - General industry, listed on NYSE, with a market capitalisation of 160 billion USD. The stock trades at 28.12 USD, close to its 52-week high.

Against trailing twelve-month earnings, the price asks 19.5 times profit, versus 19.2 times for the industry median. Return on equity stands at 8.6%, against an industry median of 21.9%. Revenue has grown 8.5% a year over the past five years.

Over the past twelve months the stock returned +16.8%, against +24.8% for SPY over the same period. The analysis below covers valuation, profitability, growth, the balance sheet and price behaviour, with data updated daily.

Key data

Price and Trading

  • OpenThe price at which Pfizer Inc shares first traded in the latest session.
  • CloseThe price of the last Pfizer Inc trade in the session that closed.
  • Day rangeThe lowest and highest price Pfizer Inc shares reached in that session.
  • VolumeHow many Pfizer Inc shares changed hands in the latest session.
  • 52-week rangeThe lowest and highest price of Pfizer Inc shares over the past year.
  • Position in the 52-week rangeWhere the current price of Pfizer Inc shares sits between the low and the high of the past year. 100% means right at the high.
  • 50-day averageThe average price of Pfizer Inc shares over the last 50 sessions. Shows the short-term trend.
  • 200-day averageThe average price of Pfizer Inc shares over the last 200 sessions. Shows the long-term trend.
  • Market capThe market value of all Pfizer Inc shares combined.

Some values update after the trading session opens, others are recalculated after it closes.

Earnings and Valuation

  • Earnings per shareHow much net profit belongs to a single Pfizer Inc share over the last twelve months.
  • Estimated earnings, current yearThe earnings per share analysts expect from Pfizer Inc for the current financial year.
  • Estimated earnings, next yearThe earnings per share expected from Pfizer Inc for the following financial year.
  • Revenue per shareHow much of the annual sales of Pfizer Inc belongs to a single share.
  • Book value per shareHow much Pfizer Inc equity belongs to one share, once debt is subtracted from assets.
  • Revenue, last 12 monthsTotal Pfizer Inc sales across the last four reported quarters.
  • Price / earningsHow many years of current profit a Pfizer Inc share costs at today price.
  • Forward price / earningsThe same ratio, but against the profit Pfizer Inc is expected to make next year.
  • PEGThe price/earnings ratio of Pfizer Inc divided by its growth rate. Below 1 is considered cheap relative to how fast it grows.
  • Enterprise value / EBITDAThe price of the whole Pfizer Inc business, debt included, against operating profit before depreciation.

Some values update after the trading session opens, others are recalculated after it closes.

Return and Risk

Low risk · 67
  • Net marginHow much net profit Pfizer Inc keeps out of every unit of sales.
  • Return on equityHow much net profit Pfizer Inc produces from shareholder money.
  • Dividend yieldHow much Pfizer Inc pays out in dividends each year, relative to the share price.
  • Dividend per shareThe estimated annual amount received for each Pfizer Inc share held.
  • Payout ratioWhat share of Pfizer Inc profit goes back to shareholders as dividends. The rest stays in the company.
  • BetaHow strongly Pfizer Inc shares move against the market. 1 means the same, above 1 means wider swings.
  • Debt / equityHow much debt Pfizer Inc carries for every unit of equity.
  • Short interest as % of floatWhat share of freely tradable Pfizer Inc stock is sold short, as a bet on a decline.
  • Days to cover short positionsHow many normal trading days it would take to close every short position on Pfizer Inc.

Some values update after the trading session opens, others are recalculated after it closes.

Indicators for Pfizer Inc (PFE) stock

How good the business is, how expensive the price is, and what the chart is doing for PFE stock. How we calculate the three indicators

Fundamentals

47.1Out of 100

Balanced

The weak point is growth, at 24.5 out of 100; highest is health and risk, at 67.0. Against its sector it stands at 53 out of 100, so the two readings confirm each other.

Quality49.9
Growth24.5
Health and risk67.0
Piotroski F-Score66.7
Low leverage61.0
Free cash flow margin59.9
Gross profitability42.3
Earnings stability27.5
Profitability27.1

Valuation

63.0Out of 100

Slightly cheap

The business produces as much a year as the interest on a government bond. It is 47% below its 52-week high.

Earnings against market capitalisation: 61.8 out of 100

Earnings yield74.3
P/E (TTM)49.3

Earnings against enterprise value: 44.1 out of 100

EV/EBIT33.3
Acquirer's multiple33.3
Magic Formula yield58.5
EVA yield51.3

Free cash flow against price: 73.4 out of 100

FCF yield73.4

Price against estimated value: 72.6 out of 100

Margin of safety37.4
Price / floor value91.7
EPV vs price88.7

Technical

-19Out of ±100

Slightly negative

Signals: 5 positive and 8 negative, but no clear trend (ADX 14): the price is going nowhere. The heaviest weight comes from the “volume and money flow” family; the “breakouts and reversals” family points the other way.

Price against the moving averages: +0.33

Price vs MA200+2.0% from the average
Price vs MA50-3.0% from the average
MA50 vs MA200Short average above the long one

MACD: 0.00

MACD histogram+0.025
MACD line vs 0-0.16

Position in the recent range: -0.67

RSI 1443.5
CCI 20-66
Bollinger %B0.28

Long-term momentum: -0.33

Aroon oscillator-56
Coppock-2.4
12-month momentum+20% a year, +15% above the rate

Volume and money flow: -1.00

Money flow CMF-0.112
OBV volume, 50dSlope -0.046

Breakouts and reversals: +0.50

Parabolic SARBelow price, rising
Donchian channelInside the 20-day channel

Pfizer Inc (PFE) stock: arguments for and against

What supports and what weakens the investment case for PFE stock

Pro12 arguments
  • Pfizer Inc (PFE) shares pay 6.1% a year on the share price.At today's price the dividend yields 6.1% a year, cash that goes straight to the shareholder. Government bonds in US pay 5.3%, but without the company's growth.
  • The business generates 6.9% in free cash flow a year, relative to its share price.After paying everything it owes and reinvesting in itself, the company is left with cash equal to 6.9% of the share price. Companies in the Healthcare sector generate 4.8%.
  • The bankruptcy model places Pfizer Inc in the safe zone.The Altman score, which predicts failures from the balance sheet, is 6.31. Below 2.60 the risk zone would begin.
  • The 50-day price average sits above the 200-day.The price sits 2.0% above its 200-day average. Many investors watch this pattern as a sign of an upward trend.
  • Money put back into the business earns more than it costs.Every unit reinvested brings 6.8% a year while funding costs 5.8%. As long as the gap stays positive, growth adds value.
  • Short-selling pressure is minimal.Only 2.0% of the freely traded shares are borrowed as a bet on a fall, and buying them back would take 3.98 trading days.
  • Institutions bought on balance last quarter: 15 funds added, 8 cut back.15 funds added to their position and 8 cut back over the past three months. Together they hold 69.4% of the company.
  • Cash from operations comes in at 1.6 times the reported profit.Profit is an accounting figure, operating cash is what actually reaches the bank account. When the second is clearly larger, the profit is backed by money rather than by entries.
  • Of the last 8 reports, 7 came in above estimates.One good quarter can be luck, a long run suggests the company knows its own numbers and guides conservatively.
  • Through Bear market 2022 it lost 30.2%, less than 73% of comparable companies.How a share fell in a past crisis does not predict the next one, but it shows how it behaves when the whole market sells at once.
  • It scores 83 out of 100 in the stress tests, and in the harshest scenario, Recesiune severă, it would lose 18.2%.The scenarios start from historical shocks and are applied to the company as it stands today. They are exercises rather than forecasts, but they rank the risk.
  • It trades $1.23B a day on average.With daily turnover that size, an ordinary order gets in and out without moving the price, and the spread stays narrow.
Against11 arguments
  • Pfizer Inc (PFE) debt is 3.98 times annual earnings from operations.At that level, a weak year leaves less room to manoeuvre. Companies in the Healthcare sector stand at 1.5.
  • Out of every 100 units sold, only 6.8% is left as profit.After all costs, taxes and interest, 6.8% of sales remains - so a rise in input or funding costs is felt quickly. Companies in the Healthcare sector retain 8.2%.
  • For shareholders, the business earns 5.0% a year - below the sector.Every unit of capital put in by shareholders brings 5.0% a year. Companies in the Healthcare sector produce 10.5%.
  • Revenue grew 8.5% a year over the past five years.Sales grew 8.5% a year over the past five years. In pharma the pace breaks when patents expire, so a weak year may mean a drug out of protection rather than a declining business. Companies in the Healthcare sector grew 9.2% a year.
  • At today's price, Pfizer Inc shares cost the equivalent of 37.0 years of earnings.If profit stays where it is, the investment would only pay for itself in 37.0 years. Companies in the Healthcare sector need 19.5 years, and the gap would close only if profit grows sharply.
  • The models find no durable competitive advantage.Without an advantage that lasts, earnings depend on how well the company is run each year rather than on its position in the market.
  • The dividend takes 225.9% of profit.Almost all the earnings go out to shareholders, so a weaker year could force a cut. Companies in the Healthcare sector pay out 33.2%.
  • The latest results from Pfizer Inc missed analyst estimates by 9.6%.The estimate is the average of the analysts covering the company, so the miss shows how far the outcome sat from what the market expected.
  • Pfizer Inc posted a loss in 1 of the last four quarters.An annual profit can hide losing quarters, because the year is a sum. The quarterly figures show whether the business was in the black throughout or only by the end.
  • Over the last twelve months, Pfizer Inc shares trailed the SPY index by 8.0 points, returning 16.8%.Anyone holding the index instead of the share would have had a better year. The gap says how much, not why.
  • Gross margin fell by 4.4 points against the same quarter a year earlier.Less of every unit of sales survives the direct cost. When the margin thins, revenue growth stops translating into profit on its own.

Verdict

The Pfizer Inc score from 0 to 100, built from over 400 financial indicators. Not investment advice.

Neutral
ExpensiveBalancedMixed
  • In Healthcare, Pfizer Inc is above the sector average on shareholder yield and stability, below it on growth.
  • neutral verdicts returned a median of +12.2% over one year, across 63,296 assessments.

At Pfizer Inc, return on capital exceeds its cost.
But the price asks 1.7 times the estimated value.

Earnings per share fell 37% a year over the past three years. Free cash flow covers 7% of the price each year. It earns just 5% a year on shareholders' money.

Analysis produced automatically by einvestitii.ro, on data as of oct. 1, 2026. It is not investment advice. Who produces it, what it rests on and what conflicts of interest exist: see the full disclosure.

What it is really worth

Value & Valuation

The market price is what buyers are asking today. Here we work out what the share should cost based on the company’s own figures: using the valuation models professional investors rely on, the growth the current price assumes, and the target set by the analysts who follow the company.

what analysts think

What the analysts covering Pfizer Inc think, and where they see the price 12 months out. These are their estimates, not ours.

Analyst consensus

What the 25 analysts covering Pfizer Inc think

Buy

average 3.56 out of 5, from 25 analysts

Strong sellStrong buy
  • Strong sell14%
  • Sell00%
  • Hold1560%
  • Buy28%
  • Strong buy728%

The analyst consensus is more optimistic than our score, by 17 points on the same 0 to 100 scale.

Analyst estimates, third-party source. These are not our verdict.

Price target

Where analysts see Pfizer Inc shares 12 months out

$29.19

+14.01% against today price

52-week low $21.5552-week high $28.28
  • today$28.12
  • target$29.19

The target falls outside the 52-week range for Pfizer Inc; the marker is capped at the end.

Rise from the low of the past year+30.46%
Fall from the high of the past year−0.58%
  • Price today$28.12
  • Revisions, last 30 days12 ↑8 ↓
  • Expected earnings growth−4.21%
  • Analysts covering25

Analyst estimates, third-party source.

Transparency · MAR

fair value

Overvalued

What Pfizer Inc shares should cost, according to the valuation models of the best-known investors in history.

Estimated fair value

The average of the Graham, Buffett, Lynch models, and others.

$16.37−41.8% versus price

the price is 1.72 times the estimate from 5 models

×0.5×1
fair range $7.21 - $25.10price today $28.12

Logarithmic scale; the marks are multiples of the fair value.

Price versus estimate 1.72×Confidence in the estimate: MediumSpread across models 77%Median of 5 models

These are estimates, not price targets: every model starts from assumptions about the future, and if the assumptions change, so does the number.

The models, one by one

7 methods with a value for Pfizer Inc. The fair value above is the median across 5 of them, chosen by how well they fit the company. All of them are here, for reference.

Graham Number$21.62−23.1% versus price
Buffett with growth$28.59+1.7% versus price
Buffett without growth$16.37−41.8% versus price
Lynch Fair Price$6.57−76.6% versus price
Earnings Power Value (EPV)$40.61+44.4% versus price
Absolute floor$28.67+1.9% versus price
DCF value$28.64+1.9% versus price

Transparency · MAR

projections

These are not predictions. The model splits the possible outcomes into ranges and reports how often the price landed in each, across similar cases in the past.

computed on 9 august 2026

Where the price could go

The price range Pfizer Inc shares could fall into, from six months out to five years

6 months

Where the price could go

The price range Pfizer Inc shares could fall into, from six months out to five years

+2.6%most likely · $26.26
Pessimistic −17%Optimistic +29%
  • Today's price$25.60
  • Median$26.26
Pessimistic scenario$21.19
Optimistic scenario$33.01

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

With what probability

Estimated chances for the next six months

No clear tilt

  • Chance it ends higher than today57%
  • Chance it beats the indexindex +4.8%47%
  • Chance of a gain over 20%17%
  • Chance of a drop over 10%21%
  • Chance of a drop over 20%8%

12 months

Where the price could go

The price range Pfizer Inc shares could fall into, from six months out to five years

+3.7%most likely · $26.54
Pessimistic −22%Optimistic +37%
  • Today's price$25.60
  • Median$26.54
Pessimistic scenario$19.85
Optimistic scenario$35.14

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

With what probability

Estimated chances for the next six months

No clear tilt

  • Chance it ends higher than today56%
  • Chance it beats the indexindex +9.6%38%
  • Chance of a gain over 20%26%
  • Chance of a drop over 10%27%
  • Chance of a drop over 20%13%

3 years

Where the price could go

The price range Pfizer Inc shares could fall into, from six months out to five years

+17.8%most likely · $30.16
Pessimistic +1%Optimistic +28%
  • Today's price$25.60
  • Median$30.16
Pessimistic scenario$25.73
Optimistic scenario$32.66

Expected growth over 3 years, per year: +5.6% per year, between +0% and +8%.

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

Where the return comes from

Today's price embeds a high expectation. The model assumes investors will, over time, pay less for the same profit, and that difference is subtracted from the annual growth.

  • earnings growth+5.5%
  • the dividend+5.2%
  • multiple re-rating−5.0%

5 years

Where the price could go

The price range Pfizer Inc shares could fall into, from six months out to five years

+28.2%most likely · $32.81
Pessimistic +1%Optimistic +41%
  • Today's price$25.60
  • Median$32.81
Pessimistic scenario$25.82
Optimistic scenario$36.14

Expected growth over 5 years, per year: +5.1% per year, between +0% and +7%.

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

Where the return comes from

Today's price embeds a high expectation. The model assumes investors will, over time, pay less for the same profit, and that difference is subtracted from the annual growth.

  • earnings growth+4.9%
  • the dividend+5.2%
  • multiple re-rating−5.0%

The estimates are generated automatically by a proprietary probabilistic machine-learning and AI model.

This information is general in nature and is not investment advice. In line with Regulation (EU) 596/2014 on market abuse and Regulation (EU) 2024/1689 on artificial intelligence. Past performance does not guarantee future results. Full methodology

Transparency · MAR

How the business is actually doing

The Business & Its Results

Fundamental analysis of Pfizer Inc (PFE) stock: how profitable the business is, how fast it grows, and how well it turns capital into profit. Across the three, the fundamental score comes to 39.8 out of 100, with quality the strong point and growth the weak one.

39.8 · weak

value43.8/100
quality49.9/100
growth24.5/100
dividends41.1/100

the business and its results

Mixed results

How profitable is it?

51 · average

Capital invested in Pfizer Inc produces 6.77% a year, and shareholders' equity 4.96%. Close to the middle of the sector.

  • Return on invested capitalProfit generated from all capital employed — equity and debt alike. Above the cost of capital (WACC) means value is created. Above 15% is very good.
  • Return on equityHow much net profit the company generates from shareholders' money. Above ~15% is very good; consistency matters as much as the level.
  • Return on assetsHow much profit the company draws from the assets it owns. Above ~5% is solid, though it varies widely by industry.
  • Gross profitabilityGross profit against assets — the quality measure proposed by Novy-Marx. High readings point to a durable competitive advantage.
  • Free cash flow marginHow much of sales is left as free cash after investment. Above ~15% is very healthy.
  • Cash operating profitabilityProfitability measured on cash actually collected, not on accounting profit. High readings mean reported profit is backed by real money.
  • ROIC − WACC spreadThe gap between the return on capital and what that capital costs. Positive means invested capital adds value. Negative means it destroys value.
  • Net margin (DuPont breakdown)The margin component of the DuPont breakdown of returns. Higher means the firm keeps more of every unit sold.

How fast does it grow?

40 · weak

Pfizer Inc revenue grew 8.48% a year over the past five years, and net profit -3.24%.

  • Revenue growth (5-year annual)Average yearly revenue growth over the past five years. Above ~10% is solid growth for a mature company.
  • Earnings per share growth (5-year annual)Average yearly growth in earnings per share. Faster than revenue means expanding margins or buybacks.
  • Free cash flow growth (5-year annual)Average yearly growth in free cash flow. Keeping pace with profit means growth is backed by real money.
  • Net income growth (5-year annual)Average yearly growth in net income. Steady and positive points to a predictable business model.
  • Rule of 40Revenue growth added to the profitability margin. Above 40 means a good balance between growth and profitability.
  • Consecutive years of dividend growthHow many years in a row the dividend per share has grown, without a single break. A long streak shows a company that can afford to raise the payout to shareholders year after year.

Is profit backed by real cash?

47 · average

The Pfizer Inc Piotroski score is 6 out of 9. The earnings quality signals are mixed.

  • Piotroski F-score (0–9)Nine financial health checks; each one passed adds a point. 7 or more means improving fundamentals.
  • Beneish M-scoreModel that detects patterns of aggressive accounting. Below −1.78 means no signals of aggressive reporting. A statistical test, not an accusation.
  • Montier C-score (0–6)Six warning signals about the quality of accounting. 0–1 is clean; 4 or above calls for caution.
  • Accruals ratio (Sloan)How much of reported profit is accounting only, rather than cash collected. Low or negative means profit is backed by real money.
  • Stock-based compensation dilutionHow much of shareholders' stake is diluted by shares granted to employees. Below 2% a year is bearable dilution.

How efficiently does it use its money?

50 · average

Money put into sales comes back to Pfizer Inc in 182 days.

  • Cash conversion cycleHow many days pass between paying suppliers and collecting from customers. Low or negative means the company funds operations with its partners' money.
  • Cash conversion cycle (5-year average)The five-year average of the conversion cycle — it shows consistency, not just this year. Stable and low means durable operational discipline.
  • Cash conversion rateHow much of accounting profit actually turns into cash. Above 100% means profit is more than covered by real money.
  • ROIC minus WACC spread (5-year average)The same gap between the return on capital and its cost, but computed on the five-year average return rather than the current year. Positive and stable means growth worth financing.

The scores are percentiles against companies in the same sector, not absolute marks. A low score means the sector is doing better, not necessarily that the figures are bad.

financial data

The income statement, balance sheet and cash flows of Pfizer Inc. Totals and main components are shown by default; the rest open from “all rows”.

revenue$62.58 bn−1.6%201620252016$52.82 bn2017$52.55 bn2018$53.65 bn2019$41.17 bn2020$41.65 bn2021$81.29 bn2022$100.33 bn2023$59.55 bn2024$63.63 bn2025$62.58 bn
operating income$15.44 bn−6.3%201620252016$14.27 bn2017$14.39 bn2018$15.29 bn2019$7.51 bn2020$9.09 bn2021$20.79 bn2022$37.55 bn2023$5.29 bn2024$16.48 bn2025$15.44 bn
net income$7.77 bn−3.1%201620252016$7.22 bn2017$21.31 bn2018$11.15 bn2019$16.27 bn2020$9.16 bn2021$22.15 bn2022$31.37 bn2023$2.13 bn2024$8.02 bn2025$7.77 bn
Income statement, annual, 6 periods
 2025Δ 202420242023202220212020
$62.58 bn100%−1.6%$63.63 bn100%$59.55 bn100%$100.33 bn100%$81.29 bn100%$41.65 bn100%

Everything the company collected from sales, before any expense. At Pfizer Inc, in 2025: $62.58 bn · Δ −1.6% (2024).

$18.57 bn29.7%−14.8%$21.78 bn34.2%$29.21 bn49.1%$38.24 bn38.1%$34.41 bn42.3%$11.77 bn28.3%

What it cost to produce what was sold: materials, labour, the factory. At Pfizer Inc, in 2025: $18.57 bn · Δ −14.8% (2024).

$44.01 bn70.3%+5.2%$41.85 bn65.8%$30.34 bn50.9%$62.09 bn61.9%$46.88 bn57.7%$29.88 bn71.7%

What is left from sales after the direct cost of the product, before admin salaries and research. At Pfizer Inc, in 2025: $44.01 bn · Δ +5.2% (2024).

gross margin70.3%70.3%65.8%65.8%50.9%50.9%61.9%61.9%57.7%57.7%71.7%71.7%
$11.98 bn19.1%+11.5%$10.74 bn16.9%$10.58 bn17.8%$11.43 bn11.4%$13.83 bn17.0%$9.40 bn22.6%

Money put into tomorrow’s products: research, engineering, software. At Pfizer Inc, in 2025: $11.98 bn · Δ +11.5% (2024).

$13.64 bn21.8%+18.9%$11.47 bn18.0%$11.07 bn18.6%$10.88 bn10.8%$10.70 bn13.2%$9.82 bn23.6%

Sales and admin salaries, marketing, rent, everything that keeps the company running. At Pfizer Inc, in 2025: $13.64 bn · Δ +18.9% (2024).

of which: selling and marketing—-$3.30 bn5.2%$3.70 bn6.2%$2.80 bn2.8%$2.00 bn2.5%$1.80 bn4.3%
$47.14 bn75.3%$47.14 bn74.1%$54.26 bn91.1%$62.78 bn62.6%$60.50 bn74.4%$32.57 bn78.2%

The sum of all costs: cost of product plus operating expenses. At Pfizer Inc, in 2025: $47.14 bn.

$28.58 bn45.7%+12.7%$25.36 bn39.9%$25.05 bn42.1%$24.54 bn24.5%$26.08 bn32.1%$20.80 bn49.9%

The sum of expenses that do not go directly into the product. At Pfizer Inc, in 2025: $28.58 bn · Δ +12.7% (2024).

$15.44 bn24.7%−6.3%$16.48 bn25.9%$5.29 bn8.9%$37.55 bn37.4%$20.79 bn25.6%$9.09 bn21.8%

Profit from the core business, before interest and tax. At Pfizer Inc, in 2025: $15.44 bn · Δ −6.3% (2024).

operating margin24.7%24.7%25.9%25.9%8.9%8.9%37.4%37.4%25.6%25.6%21.8%21.8%
$15.10 bn24.1%−16.7%$18.13 bn28.5%$9.56 bn16.0%$41.03 bn40.9%$30.79 bn37.9%$13.17 bn31.6%

Profit before interest, tax and depreciation. Close to the cash the business produces. At Pfizer Inc, in 2025: $15.10 bn · Δ −16.7% (2024).

$10.19 bn16.3%−8.3%$11.11 bn17.5%$3.27 bn5.5%$35.97 bn35.8%$25.60 bn31.5%$8.49 bn20.4%

Profit before interest and tax. At Pfizer Inc, in 2025: $10.19 bn · Δ −8.3% (2024).

Depreciation and amortisation$4.91 bn7.8%−30.1%$7.01 bn11.0%$6.29 bn10.6%$5.06 bn5.0%$5.19 bn6.4%$4.68 bn11.2%
Reconciled depreciation$6.59 bn10.5%−6.0%$7.01 bn11.0%$6.29 bn10.6%$3.61 bn3.6%$3.70 bn4.6%$4.78 bn11.5%
Interest income$2.14 bn3.4%+292%$545.0 m0.9%$1.62 bn2.7%$1.82 bn1.8%$560.0 m0.7%$538.0 m1.3%
Interest expense$2.67 bn4.3%−13.6%$3.09 bn4.9%$2.21 bn3.7%$1.24 bn1.2%$1.29 bn1.6%$1.45 bn3.5%
Net interest income−$2.07 bn-3.3%+18.8%−$2.55 bn-4.0%−$585.0 m-1.0%−$987.0 m-1.0%−$1.26 bn-1.5%−$1.38 bn-3.3%
—-—-—-−$217.0 m-0.2%$4.88 bn6.0%−$663.0 m-1.6%

Gains and losses that do not come from the core business.

−$7.92 bn-12.7%+6.4%−$8.46 bn-13.3%−$4.23 bn-7.1%−$2.82 bn-2.8%$3.52 bn4.3%−$2.05 bn-4.9%

The balance of all non-operating income and expense. At Pfizer Inc, in 2025: −$7.92 bn · Δ +6.4% (2024).

$25.0 m0.0%+127%$11.0 m0.0%−$15.0 m0.0%$6.0 m0.0%−$434.0 m-0.5%$2.63 bn6.3%

Gains or losses that do not repeat and do not belong to normal operations. At Pfizer Inc, in 2025: $25.0 m · Δ +127% (2024).

$7.52 bn12.0%−6.3%$8.02 bn12.6%$1.06 bn1.8%$34.73 bn34.6%$24.31 bn29.9%$7.04 bn16.9%

Profit left after interest, but before the state takes its share. At Pfizer Inc, in 2025: $7.52 bn · Δ −6.3% (2024).

−$266.0 m-0.4%−850%−$28.0 m0.0%−$1.11 bn-1.9%$3.33 bn3.3%$1.85 bn2.3%$370.0 m0.9%

Income tax owed for the period. At Pfizer Inc, in 2025: −$266.0 m · Δ −850% (2024).

Tax provision−$266.0 m-0.4%−850%−$28.0 m0.0%−$1.12 bn-1.9%$3.33 bn3.3%$1.85 bn2.3%$477.0 m1.1%
Minority interest−$41.0 m-0.1%−32.3%−$31.0 m0.0%−$39.0 m-0.1%−$35.0 m0.0%−$45.0 m-0.1%$36.0 m0.1%
$7.79 bn12.4%−3.3%$8.05 bn12.7%$2.17 bn3.6%$31.40 bn31.3%$22.46 bn27.6%$7.02 bn16.9%

Profit from the businesses the company will still have next year. At Pfizer Inc, in 2025: $7.79 bn · Δ −3.3% (2024).

$7.77 bn12.4%−3.1%$8.02 bn12.6%$2.13 bn3.6%$31.37 bn31.3%$22.15 bn27.2%$9.16 bn22.0%

The profit left for shareholders after absolutely every expense. At Pfizer Inc, in 2025: $7.77 bn · Δ −3.1% (2024).

net margin12.4%12.4%12.6%12.6%3.6%3.6%31.3%31.3%27.2%27.2%22.0%22.0%
$7.77 bn12.4%−3.2%$8.03 bn12.6%$2.12 bn3.6%$31.37 bn31.3%$21.98 bn27.0%$9.62 bn23.1%

The share of profit that belongs to ordinary shares. At Pfizer Inc, in 2025: $7.77 bn · Δ −3.2% (2024).

nonRecurring—-—-—-$2.33 bn2.3%$802.0 m1.0%$600.0 m1.4%
discontinuedOperations—-—-—-$6.0 m0.0%−$434.0 m-0.5%$2.63 bn6.3%
revenue$14.45 bn+5.4%Q2 24Q1 26Q2 24$13.28 bnQ3 24$17.70 bnQ4 24$17.76 bnQ1 25$13.72 bnQ2 25$14.65 bnQ3 25$16.65 bnQ4 25$17.56 bnQ1 26$14.45 bn
operating income$4.03 bn−12.8%Q2 24Q1 26Q2 24$1.88 bnQ3 24$4.97 bnQ4 24$5.73 bnQ1 25$4.62 bnQ2 25$3.58 bnQ3 25$3.55 bnQ4 25$3.69 bnQ1 26$4.03 bn
net income$2.69 bn−9.4%Q2 24Q1 26Q2 24$24.0 mQ3 24$4.47 bnQ4 24$403.0 mQ1 25$2.97 bnQ2 25$2.91 bnQ3 25$3.54 bnQ4 25−$1.65 bnQ1 26$2.69 bn
Income statement, quarterly, 6 periods
 Q1 26Δ Q1 25Q4 25Q3 25Q2 25Q1 25Q4 24
$14.45 bn100%+5.4%$17.56 bn100%$16.65 bn100%$14.65 bn100%$13.72 bn100%$17.76 bn100%

Everything the company collected from sales, before any expense. At Pfizer Inc, in Q1 26: $14.45 bn · Δ +5.4% (Q1 25).

$4.73 bn32.7%+21.7%$5.27 bn30.0%$4.17 bn25.1%$5.23 bn35.7%$3.89 bn28.3%$4.80 bn27.0%

What it cost to produce what was sold: materials, labour, the factory. At Pfizer Inc, in Q1 26: $4.73 bn · Δ +21.7% (Q1 25).

$9.72 bn67.3%−1.1%$12.29 bn70.0%$12.48 bn74.9%$9.42 bn64.3%$9.83 bn71.7%$12.97 bn73.0%

What is left from sales after the direct cost of the product, before admin salaries and research. At Pfizer Inc, in Q1 26: $9.72 bn · Δ −1.1% (Q1 25).

gross margin67.3%67.3%70.0%70.0%74.9%74.9%64.3%64.3%71.7%71.7%73.0%73.0%
$2.63 bn18.2%+20.6%$3.42 bn19.5%$3.94 bn23.6%$2.44 bn16.7%$2.18 bn15.9%$3.02 bn17.0%

Money put into tomorrow’s products: research, engineering, software. At Pfizer Inc, in Q1 26: $2.63 bn · Δ +20.6% (Q1 25).

$2.96 bn20.5%−2.3%$4.08 bn23.2%$3.19 bn19.1%$3.42 bn23.3%$3.03 bn22.1%$1.44 bn8.1%

Sales and admin salaries, marketing, rent, everything that keeps the company running. At Pfizer Inc, in Q1 26: $2.96 bn · Δ −2.3% (Q1 25).

of which: selling and marketing—-—-—-—-—-$3.30 bn18.6%
$10.42 bn72.1%+14.6%$13.87 bn79.0%$13.10 bn78.7%$11.08 bn75.6%$9.09 bn66.3%$12.04 bn67.8%

The sum of all costs: cost of product plus operating expenses. At Pfizer Inc, in Q1 26: $10.42 bn · Δ +14.6% (Q1 25).

$5.69 bn39.4%+9.3%$8.60 bn49.0%$8.93 bn53.6%$5.85 bn39.9%$5.20 bn37.9%$7.24 bn40.8%

The sum of expenses that do not go directly into the product. At Pfizer Inc, in Q1 26: $5.69 bn · Δ +9.3% (Q1 25).

$4.03 bn27.9%−12.8%$3.69 bn21.0%$3.55 bn21.3%$3.58 bn24.4%$4.62 bn33.7%$5.73 bn32.2%

Profit from the core business, before interest and tax. At Pfizer Inc, in Q1 26: $4.03 bn · Δ −12.8% (Q1 25).

operating margin27.9%27.9%21.0%21.0%21.3%21.3%24.4%24.4%33.7%33.7%32.2%32.2%
$5.22 bn36.1%+3.1%$756.0 m4.3%$5.65 bn33.9%$5.32 bn36.3%$5.06 bn36.9%$5.14 bn29.0%

Profit before interest, tax and depreciation. Close to the cash the business produces. At Pfizer Inc, in Q1 26: $5.22 bn · Δ +3.1% (Q1 25).

$4.03 bn27.9%+17.3%−$931.0 m-5.3%$3.99 bn23.9%$3.70 bn25.2%$3.44 bn25.1%$3.35 bn18.9%

Profit before interest and tax. At Pfizer Inc, in Q1 26: $4.03 bn · Δ +17.3% (Q1 25).

Depreciation and amortisation$1.18 bn8.2%−26.9%$1.69 bn9.6%$1.66 bn10.0%$1.63 bn11.1%$1.62 bn11.8%$1.79 bn10.1%
Reconciled depreciation$1.61 bn11.2%−0.3%$1.69 bn9.6%$1.66 bn10.0%$1.63 bn11.1%$1.62 bn11.8%$1.79 bn10.1%
Interest income$115.0 m0.8%−19.6%$517.0 m2.9%$138.0 m0.8%$156.0 m1.1%$143.0 m1.0%$171.0 m1.0%
Interest expense$668.0 m4.6%+2.1%$711.0 m4.0%$652.0 m3.9%$654.0 m4.5%$654.0 m4.8%$739.0 m4.2%
Net interest income−$553.0 m-3.8%−8.2%−$545.0 m-3.1%−$514.0 m-3.1%−$498.0 m-3.4%−$511.0 m-3.7%−$568.0 m-3.2%
−$862.0 m-6.0%+53.2%−$5.33 bn-30.4%−$216.0 m-1.3%−$531.0 m-3.6%−$1.84 bn-13.4%−$5.74 bn-32.3%

The balance of all non-operating income and expense. At Pfizer Inc, in Q1 26: −$862.0 m · Δ +53.2% (Q1 25).

—-$00.0%$00.0%$25.0 m0.2%$00.0%$7.0 m0.0%

Gains or losses that do not repeat and do not belong to normal operations.

$3.17 bn21.9%+13.9%−$1.64 bn-9.4%$3.33 bn20.0%$3.04 bn20.8%$2.78 bn20.3%−$10.0 m-0.1%

Profit left after interest, but before the state takes its share. At Pfizer Inc, in Q1 26: $3.17 bn · Δ +13.9% (Q1 25).

$461.0 m3.2%+344%−$2.0 m0.0%−$216.0 m-1.3%$141.0 m1.0%−$189.0 m-1.4%−$421.0 m-2.4%

Income tax owed for the period. At Pfizer Inc, in Q1 26: $461.0 m · Δ +344% (Q1 25).

Tax provision$461.0 m3.2%+344%−$2.0 m0.0%−$216.0 m-1.3%$141.0 m1.0%−$189.0 m-1.4%−$421.0 m-2.4%
Minority interest−$8.0 m-0.1%−33.3%−$8.0 m0.0%−$9.0 m-0.1%−$18.0 m-0.1%−$6.0 m0.0%−$8.0 m0.0%
$2.71 bn18.7%−8.9%−$1.64 bn-9.3%$3.55 bn21.3%$2.90 bn19.8%$2.97 bn21.7%$411.0 m2.3%

Profit from the businesses the company will still have next year. At Pfizer Inc, in Q1 26: $2.71 bn · Δ −8.9% (Q1 25).

$2.69 bn18.6%−9.4%−$1.65 bn-9.4%$3.54 bn21.3%$2.91 bn19.9%$2.97 bn21.6%$403.0 m2.3%

The profit left for shareholders after absolutely every expense. At Pfizer Inc, in Q1 26: $2.69 bn · Δ −9.4% (Q1 25).

net margin18.6%18.6%-9.4%-9.4%21.3%21.3%19.9%19.9%21.6%21.6%2.3%2.3%
—-−$1.65 bn-9.4%$3.54 bn21.3%$2.91 bn19.9%$2.97 bn21.6%$410.0 m2.3%

The share of profit that belongs to ordinary shares.

total assets$208.16 bn−2.5%201620252016$171.62 bn2017$171.80 bn2018$159.42 bn2019$167.49 bn2020$154.23 bn2021$181.48 bn2022$197.21 bn2023$226.50 bn2024$213.40 bn2025$208.16 bn
total liabilities$121.39 bn−2.8%201620252016$111.78 bn2017$100.14 bn2018$95.66 bn2019$104.04 bn2020$90.76 bn2021$104.01 bn2022$101.29 bn2023$137.21 bn2024$124.90 bn2025$121.39 bn
shareholders equity$86.48 bn−2.0%201620252016$59.84 bn2017$71.66 bn2018$63.76 bn2019$63.45 bn2020$63.47 bn2021$77.46 bn2022$95.92 bn2023$89.29 bn2024$88.20 bn2025$86.48 bn
Balance sheet, annual, 6 periods
 2025Δ 202420242023202220212020
$208.16 bn100%−2.5%$213.40 bn100%$226.50 bn100%$197.21 bn100%$181.48 bn100%$154.23 bn100%

Everything the company owns: factories, inventory, cash, receivables. At Pfizer Inc, in 2025: $208.16 bn · Δ −2.5% (2024).

$42.90 bn20.6%−14.8%$50.36 bn23.6%$43.33 bn19.1%$51.26 bn26.0%$59.69 bn32.9%$35.07 bn22.7%

What turns into money in less than a year. At Pfizer Inc, in 2025: $42.90 bn · Δ −14.8% (2024).

Cash$1.14 bn0.5%+9.5%$1.04 bn0.5%$2.85 bn1.3%$416.0 m0.2%$1.94 bn1.1%$1.78 bn1.2%
Cash and equivalents$1.14 bn0.5%+9.5%$1.04 bn0.5%$2.85 bn1.3%$416.0 m0.2%$1.94 bn1.1%$1.78 bn1.2%
Short-term investments$12.45 bn6.0%−35.9%$19.43 bn9.1%$9.84 bn4.3%$22.32 bn11.3%$29.13 bn16.0%$10.44 bn6.8%
Cash and short-term investments$13.60 bn6.5%−33.6%$20.48 bn9.6%$12.69 bn5.6%$22.73 bn11.5%$31.07 bn17.1%$12.22 bn7.9%
Net receivables$11.87 bn5.7%−19.6%$14.78 bn6.9%$11.18 bn4.9%$14.53 bn7.4%$15.75 bn8.7%$11.19 bn7.3%
Inventory$10.65 bn5.1%−1.8%$10.85 bn5.1%$10.19 bn4.5%$8.98 bn4.6%$9.06 bn5.0%$8.05 bn5.2%
Other current assets$6.77 bn3.3%+59.3%$4.25 bn2.0%$9.28 bn4.1%$5.02 bn2.5%$3.82 bn2.1%$3.44 bn2.2%
$165.26 bn79.4%+1.4%$163.04 bn76.4%$183.17 bn80.9%$145.94 bn74.0%$121.78 bn67.1%$119.16 bn77.3%

What stays in the company for years: buildings, machinery, licences. At Pfizer Inc, in 2025: $165.26 bn · Δ +1.4% (2024).

Property, plant and equipment$21.53 bn10.3%+4.1%$20.68 bn9.7%$18.94 bn8.4%$16.27 bn8.3%$14.88 bn8.2%$13.90 bn9.0%
PP&E, net$21.53 bn10.3%+17.1%$18.39 bn8.6%$18.94 bn8.4%$16.27 bn8.3%$14.88 bn8.2%$13.90 bn9.0%
$36.70 bn17.6%+5.2%$34.88 bn16.3%$34.99 bn15.4%$31.45 bn15.9%$29.96 bn16.5%$28.41 bn18.4%

The purchase value of buildings and machinery, before accumulated depreciation. That is why it exceeds the net value. At Pfizer Inc, in 2025: $36.70 bn · Δ +5.2% (2024).

Goodwill$71.26 bn34.2%+4.0%$68.53 bn32.1%$67.78 bn29.9%$51.38 bn26.1%$49.21 bn27.1%$49.58 bn32.1%
Intangible assets$53.73 bn25.8%−3.0%$55.41 bn26.0%$64.90 bn28.7%$43.37 bn22.0%$25.15 bn13.9%$28.47 bn18.5%
Long-term investments$1.62 bn0.8%−27.2%$2.23 bn1.0%$15.37 bn6.8%$15.07 bn7.6%$21.53 bn11.9%$20.26 bn13.1%
Other non-current assets$7.30 bn3.5%−25.6%$9.82 bn4.6%$9.15 bn4.0%$13.16 bn6.7%$7.68 bn4.2%$4.57 bn3.0%
Other assets$17.12 bn8.2%+5.7%$16.19 bn7.6%$6.71 bn3.0%$6.81 bn3.5%$5.58 bn3.1%$4.28 bn2.8%
$121.39 bn58.3%−2.8%$124.90 bn58.5%$137.21 bn60.6%$101.29 bn51.4%$104.01 bn57.3%$90.76 bn58.8%

Everything the company owes, to banks and suppliers alike. At Pfizer Inc, in 2025: $121.39 bn · Δ −2.8% (2024).

$36.98 bn17.8%−14.0%$43.00 bn20.1%$47.79 bn21.1%$42.14 bn21.4%$42.67 bn23.5%$25.92 bn16.8%

Debts due in less than a year. At Pfizer Inc, in 2025: $36.98 bn · Δ −14.0% (2024).

Accounts payable$5.24 bn2.5%−7.0%$5.63 bn2.6%$6.71 bn3.0%$6.81 bn3.5%$5.58 bn3.1%$4.31 bn2.8%
Short-term debt$3.48 bn1.7%−52.3%$7.30 bn3.4%$10.88 bn4.8%$2.95 bn1.5%$2.24 bn1.2%$2.70 bn1.8%
Current portion of long-term debt$3.15 bn1.5%−54.6%$6.95 bn3.3%$10.35 bn4.6%$2.95 bn1.5%$2.24 bn1.2%$2.70 bn1.8%
Deferred revenue$784.0 m0.4%−48.1%$1.51 bn0.7%$2.70 bn1.2%$2.52 bn1.3%$3.07 bn1.7%$6.27 bn4.1%
Other current liabilities$27.48 bn13.2%−3.8%$28.55 bn13.4%$27.51 bn12.1%$29.86 bn15.1%$31.79 bn17.5%$12.64 bn8.2%
$84.40 bn40.5%+3.0%$81.90 bn38.4%$89.42 bn39.5%$59.15 bn30.0%$61.34 bn33.8%$64.84 bn42.0%

Debts due beyond one year. At Pfizer Inc, in 2025: $84.40 bn · Δ +3.0% (2024).

Long-term debt$60.81 bn29.2%+7.2%$56.70 bn26.6%$60.50 bn26.7%$32.88 bn16.7%$36.20 bn19.9%$37.13 bn24.1%
Total long-term debt$61.64 bn29.6%+7.4%$57.41 bn26.9%$61.54 bn27.2%$32.88 bn16.7%$36.20 bn19.9%$37.13 bn24.1%
Other non-current liabilities$14.73 bn7.1%+4.1%$14.15 bn6.6%$16.54 bn7.3%$25.24 bn12.8%$9.74 bn5.4%$23.64 bn15.3%
of which: deferred liabilities—-—-$640.0 m0.3%$1.02 bn0.5%$349.0 m0.2%$4.06 bn2.6%
Other liabilities—-—-—-$23.35 bn11.8%$22.64 bn12.5%$26.59 bn17.2%
$86.48 bn41.5%−2.0%$88.20 bn41.3%$89.29 bn39.4%$95.92 bn48.6%$77.46 bn42.7%$63.47 bn41.2%

What would be left for shareholders if everything were sold and every debt paid. At Pfizer Inc, in 2025: $86.48 bn · Δ −2.0% (2024).

$481.0 m0.2%+0.2%$480.0 m0.2%$478.0 m0.2%$476.0 m0.2%$473.0 m0.3%$470.0 m0.3%

Money put in by shareholders at founding and at capital raises. At Pfizer Inc, in 2025: $481.0 m · Δ +0.2% (2024).

$481.0 m0.2%+0.2%$480.0 m0.2%$478.0 m0.2%$476.0 m0.2%$473.0 m0.3%$470.0 m0.3%

Capital subscribed by shareholders. At Pfizer Inc, in 2025: $481.0 m · Δ +0.2% (2024).

$94.47 bn45.4%+0.9%$93.60 bn43.9%$92.63 bn40.9%$91.80 bn46.6%$90.59 bn49.9%$88.67 bn57.5%

What was paid above the nominal value of the shares. At Pfizer Inc, in 2025: $94.47 bn · Δ +0.9% (2024).

—-—-$92.63 bn40.9%$91.80 bn46.6%$90.59 bn49.9%$88.67 bn57.5%

What shareholders paid above the nominal value of the shares.

$114.61 bn55.1%−1.8%$116.73 bn54.7%$118.35 bn52.3%$125.66 bn63.7%$103.39 bn57.0%$96.77 bn62.7%

Past years’ profits the company kept instead of distributing. At Pfizer Inc, in 2025: $114.61 bn · Δ −1.8% (2024).

Retained earnings, total—-—-$118.35 bn52.3%$125.66 bn63.7%$103.39 bn57.0%$96.77 bn62.7%
Accumulated other comprehensive income−$8.07 bn-3.9%−2.9%−$7.84 bn-3.7%−$7.96 bn-3.5%−$8.30 bn-4.2%−$5.90 bn-3.2%−$11.69 bn-7.6%
Other equity items−$20.55 bn-9.9%+2.9%−$21.16 bn-9.9%−$21.86 bn-9.6%−$22.17 bn-11.2%−$20.77 bn-11.4%−$22.31 bn-14.5%
—-—-−$114.49 bn-50.5%−$113.97 bn-57.8%−$111.36 bn-61.4%−$110.99 bn-72.0%

Own shares bought back by the company and taken out of circulation.

Common stock, total—-—-$478.0 m0.2%$476.0 m0.2%$473.0 m0.3%$470.0 m0.3%
Non-controlling interests—-—-$274.0 m0.1%$256.0 m0.1%$262.0 m0.1%$235.0 m0.2%
$208.16 bn100%−2.5%$213.40 bn100%$226.50 bn100%$197.21 bn100%$181.48 bn100%$154.23 bn100%

Liabilities plus equity. Must equal total assets. At Pfizer Inc, in 2025: $208.16 bn · Δ −2.5% (2024).

$66.27 bn31.8%+0.5%$65.95 bn30.9%$72.19 bn31.9%$34.45 bn17.5%$35.05 bn19.3%$36.49 bn23.7%

Debt left after subtracting cash in the bank. Negative means more money than debt. At Pfizer Inc, in 2025: $66.27 bn · Δ +0.5% (2024).

$67.42 bn32.4%+0.6%$66.99 bn31.4%$75.04 bn33.1%$35.83 bn18.2%$38.44 bn21.2%$39.84 bn25.8%

All borrowings, short and long term. At Pfizer Inc, in 2025: $67.42 bn · Δ +0.6% (2024).

$5.91 bn2.8%−19.7%$7.36 bn3.5%−$4.46 bn-2.0%$9.12 bn4.6%$17.02 bn9.4%$9.15 bn5.9%

The difference between what it collects and what it pays in the short term. At Pfizer Inc, in 2025: $5.91 bn · Δ −19.7% (2024).

—-—-$89.01 bn39.3%$95.66 bn48.5%$77.20 bn42.5%$63.24 bn41.0%

Assets without goodwill and licences, that is only what can be touched.

$150.44 bn72.3%−0.9%$151.85 bn71.2%$159.86 bn70.6%$130.53 bn66.2%$114.20 bn62.9%$101.51 bn65.8%

The capital the business actually has at work. At Pfizer Inc, in 2025: $150.44 bn · Δ −0.9% (2024).

5.69 bn-−0.2%5.70 bn-5.71 bn-5.73 bn-5.71 bn-5.63 bn-

How many shares exist. If the number rises, each shareholder’s slice shrinks. At Pfizer Inc, in 2025: $5.69 bn · Δ −0.2% (2024).

total assets$207.62 bn−0.2%Q2 24Q1 26Q2 24$216.19 bnQ3 24$219.48 bnQ4 24$213.40 bnQ1 25$208.03 bnQ2 25$206.10 bnQ3 25$208.73 bnQ4 25$208.16 bnQ1 26$207.62 bn
total liabilities$117.21 bn−0.2%Q2 24Q1 26Q2 24$128.22 bnQ3 24$126.92 bnQ4 24$124.90 bnQ1 25$117.39 bnQ2 25$117.08 bnQ3 25$115.64 bnQ4 25$121.39 bnQ1 26$117.21 bn
shareholders equity$90.10 bn−0.3%Q2 24Q1 26Q2 24$87.70 bnQ3 24$92.29 bnQ4 24$88.20 bnQ1 25$90.34 bnQ2 25$88.70 bnQ3 25$92.80 bnQ4 25$86.48 bnQ1 26$90.10 bn
Balance sheet, quarterly, 6 periods
 Q1 26Δ Q1 25Q4 25Q3 25Q2 25Q1 25Q4 24
$207.62 bn100%−0.2%$208.16 bn100%$208.73 bn100%$206.10 bn100%$208.03 bn100%$213.40 bn100%

Everything the company owns: factories, inventory, cash, receivables. At Pfizer Inc, in Q1 26: $207.62 bn · Δ −0.2% (Q1 25).

$42.82 bn20.6%−6.6%$42.90 bn20.6%$46.92 bn22.5%$43.70 bn21.2%$45.86 bn22.0%$50.36 bn23.6%

What turns into money in less than a year. At Pfizer Inc, in Q1 26: $42.82 bn · Δ −6.6% (Q1 25).

Cash$1.70 bn0.8%+19.1%$1.14 bn0.5%$1.34 bn0.6%$1.64 bn0.8%$1.43 bn0.7%$1.04 bn0.5%
Cash and equivalents—-$1.14 bn0.5%$1.34 bn0.6%$1.64 bn0.8%$1.43 bn0.7%$1.04 bn0.5%
Short-term investments$11.37 bn5.5%−28.4%$12.45 bn6.0%$13.64 bn6.5%$11.61 bn5.6%$15.89 bn7.6%$19.43 bn9.1%
Cash and short-term investments$13.08 bn6.3%−24.5%$13.60 bn6.5%$14.98 bn7.2%$13.25 bn6.4%$17.32 bn8.3%$20.48 bn9.6%
Net receivables$12.59 bn6.1%−14.6%$11.87 bn5.7%$14.26 bn6.8%$12.08 bn5.9%$14.75 bn7.1%$14.78 bn6.9%
Inventory$10.67 bn5.1%−1.7%$10.65 bn5.1%$11.47 bn5.5%$11.67 bn5.7%$10.85 bn5.2%$10.85 bn5.1%
Other current assets$6.50 bn3.1%+120%$6.77 bn3.3%$6.21 bn3.0%$6.71 bn3.3%$2.95 bn1.4%$4.25 bn2.0%
$164.80 bn79.4%+1.6%$165.26 bn79.4%$161.81 bn77.5%$162.39 bn78.8%$162.17 bn78.0%$163.04 bn76.4%

What stays in the company for years: buildings, machinery, licences. At Pfizer Inc, in Q1 26: $164.80 bn · Δ +1.6% (Q1 25).

Property, plant and equipment—-$19.32 bn9.3%$18.88 bn9.0%$18.78 bn9.1%$18.35 bn8.8%$18.39 bn8.6%
PP&E, net$19.40 bn9.3%+5.8%$21.53 bn10.3%$18.88 bn9.0%$18.78 bn9.1%$18.35 bn8.8%$18.39 bn8.6%
$37.21 bn17.9%+5.7%$36.70 bn17.6%$36.39 bn17.4%$36.04 bn17.5%$35.19 bn16.9%$34.88 bn16.3%

The purchase value of buildings and machinery, before accumulated depreciation. That is why it exceeds the net value. At Pfizer Inc, in Q1 26: $37.21 bn · Δ +5.7% (Q1 25).

Goodwill$71.41 bn34.4%+4.3%$71.26 bn34.2%$69.10 bn33.1%$69.00 bn33.5%$68.44 bn32.9%$68.53 bn32.1%
Intangible assets$52.56 bn25.3%−2.6%$53.73 bn25.8%$51.32 bn24.6%$52.70 bn25.6%$53.97 bn25.9%$55.41 bn26.0%
Long-term investments$1.63 bn0.8%−19.3%$1.62 bn0.8%$2.14 bn1.0%$2.12 bn1.0%$2.01 bn1.0%$2.23 bn1.0%
Other non-current assets$9.84 bn4.7%−0.1%$7.30 bn3.5%$9.32 bn4.5%$11.35 bn5.5%$9.85 bn4.7%$9.82 bn4.6%
Other assets—-$19.33 bn9.3%$20.37 bn9.8%$19.80 bn9.6%$1.0 m0.0%$40.41 bn18.9%
$117.21 bn56.5%−0.2%$121.39 bn58.3%$115.64 bn55.4%$117.08 bn56.8%$117.39 bn56.4%$124.90 bn58.5%

Everything the company owes, to banks and suppliers alike. At Pfizer Inc, in Q1 26: $117.21 bn · Δ −0.2% (Q1 25).

$34.35 bn16.5%−5.8%$36.98 bn17.8%$36.60 bn17.5%$37.73 bn18.3%$36.45 bn17.5%$43.00 bn20.1%

Debts due in less than a year. At Pfizer Inc, in Q1 26: $34.35 bn · Δ −5.8% (Q1 25).

Accounts payable$4.51 bn2.2%−14.0%$5.24 bn2.5%$5.02 bn2.4%$5.17 bn2.5%$5.24 bn2.5%$5.63 bn2.6%
Short-term debt$3.89 bn1.9%−13.0%$3.48 bn1.7%$4.30 bn2.1%$4.30 bn2.1%$4.47 bn2.1%$6.95 bn3.3%
Current portion of long-term debt$3.89 bn1.9%−13.0%$3.15 bn1.5%$4.30 bn2.1%$4.30 bn2.1%$4.47 bn2.1%$6.95 bn3.3%
Deferred revenue—-$784.0 m0.4%$924.0 m0.4%$1.12 bn0.5%$1.01 bn0.5%$1.51 bn0.7%
Other current liabilities$22.82 bn11.0%−11.3%$27.48 bn13.2%$22.55 bn10.8%$23.47 bn11.4%$25.73 bn12.4%$26.00 bn12.2%
$82.87 bn39.9%+2.4%$84.40 bn40.5%$79.04 bn37.9%$79.36 bn38.5%$80.94 bn38.9%$81.90 bn38.4%

Debts due beyond one year. At Pfizer Inc, in Q1 26: $82.87 bn · Δ +2.4% (Q1 25).

Long-term debt$59.84 bn28.8%+5.3%$60.81 bn29.2%$56.55 bn27.1%$56.63 bn27.5%$56.82 bn27.3%$56.70 bn26.6%
Total long-term debt—-$61.64 bn29.6%$57.41 bn27.5%$57.50 bn27.9%$57.64 bn27.7%$57.41 bn26.9%
Other non-current liabilities$14.20 bn6.8%+6.8%$14.73 bn7.1%$13.61 bn6.5%$13.93 bn6.8%$13.30 bn6.4%$14.15 bn6.6%
$90.10 bn43.4%−0.3%$86.48 bn41.5%$92.80 bn44.5%$88.70 bn43.0%$90.34 bn43.4%$88.20 bn41.3%

What would be left for shareholders if everything were sold and every debt paid. At Pfizer Inc, in Q1 26: $90.10 bn · Δ −0.3% (Q1 25).

$482.0 m0.2%+0.2%$481.0 m0.2%$481.0 m0.2%$481.0 m0.2%$481.0 m0.2%$480.0 m0.2%

Money put in by shareholders at founding and at capital raises. At Pfizer Inc, in Q1 26: $482.0 m · Δ +0.2% (Q1 25).

$482.0 m0.2%+0.2%$481.0 m0.2%$481.0 m0.2%$481.0 m0.2%$481.0 m0.2%$480.0 m0.2%

Capital subscribed by shareholders. At Pfizer Inc, in Q1 26: $482.0 m · Δ +0.2% (Q1 25).

—-$94.47 bn45.4%$94.25 bn45.2%$94.05 bn45.6%$93.86 bn45.1%$93.60 bn43.9%

What was paid above the nominal value of the shares.

$117.24 bn56.5%−2.0%$114.61 bn55.1%$121.15 bn58.0%$117.61 bn57.1%$119.59 bn57.5%$116.73 bn54.7%

Past years’ profits the company kept instead of distributing. At Pfizer Inc, in Q1 26: $117.24 bn · Δ −2.0% (Q1 25).

Accumulated other comprehensive income−$7.20 bn-3.5%+16.1%−$8.07 bn-3.9%−$8.07 bn-3.9%−$8.44 bn-4.1%−$8.58 bn-4.1%−$7.84 bn-3.7%
Other equity items−$20.42 bn-9.8%+3.5%−$20.55 bn-9.9%−$20.76 bn-9.9%−$20.96 bn-10.2%−$21.15 bn-10.2%−$21.16 bn-9.9%
$207.62 bn100%−0.2%$208.16 bn100%$208.73 bn100%$206.10 bn100%$208.03 bn100%$213.40 bn100%

Liabilities plus equity. Must equal total assets. At Pfizer Inc, in Q1 26: $207.62 bn · Δ −0.2% (Q1 25).

$62.75 bn30.2%+4.8%$66.27 bn31.8%$60.37 bn28.9%$60.16 bn29.2%$59.86 bn28.8%$62.61 bn29.3%

Debt left after subtracting cash in the bank. Negative means more money than debt. At Pfizer Inc, in Q1 26: $62.75 bn · Δ +4.8% (Q1 25).

$64.46 bn31.0%+5.2%$67.42 bn32.4%$61.71 bn29.6%$61.80 bn30.0%$61.29 bn29.5%$63.65 bn29.8%

All borrowings, short and long term. At Pfizer Inc, in Q1 26: $64.46 bn · Δ +5.2% (Q1 25).

$8.47 bn4.1%−9.9%$5.91 bn2.8%$10.33 bn4.9%$5.98 bn2.9%$9.41 bn4.5%$7.36 bn3.5%

The difference between what it collects and what it pays in the short term. At Pfizer Inc, in Q1 26: $8.47 bn · Δ −9.9% (Q1 25).

$153.83 bn74.1%+1.5%$150.44 bn72.3%$153.65 bn73.6%$149.62 bn72.6%$151.63 bn72.9%$151.85 bn71.2%

The capital the business actually has at work. At Pfizer Inc, in Q1 26: $153.83 bn · Δ +1.5% (Q1 25).

5.73 bn-+0.4%5.69 bn-5.71 bn-5.71 bn-5.71 bn-5.70 bn-

How many shares exist. If the number rises, each shareholder’s slice shrinks. At Pfizer Inc, in Q1 26: $5.73 bn · Δ +0.4% (Q1 25).

from operations$11.71 bn−8.2%201620252016$15.90 bn2017$16.47 bn2018$15.83 bn2019$12.59 bn2020$14.40 bn2021$32.58 bn2022$29.27 bn2023$8.70 bn2024$12.74 bn2025$11.71 bn
from investing−$1.35 bn−151%201620252016−$7.81 bn2017−$4.74 bn2018$4.53 bn2019−$3.95 bn2020−$4.27 bn2021−$22.55 bn2022−$15.78 bn2023−$32.28 bn2024$2.65 bn2025−$1.35 bn
from financing−$10.30 bn+39.9%201620252016−$8.92 bn2017−$13.04 bn2018−$20.44 bn2019−$8.49 bn2020−$9.65 bn2021−$9.82 bn2022−$14.83 bn2023$26.07 bn2024−$17.14 bn2025−$10.30 bn
Cash flows, annual, 6 periods
 2025Δ 202420242023202220212020
$7.75 bn-−3.8%$8.05 bn-$2.17 bn-$31.40 bn-$22.46 bn-$7.02 bn-

The profit left for shareholders after absolutely every expense. At Pfizer Inc, in 2025: $7.75 bn · Δ −3.8% (2024).

$6.59 bn-−6.0%$7.01 bn-$6.29 bn-$5.06 bn-$5.19 bn-$4.78 bn-

The accounting wear on buildings and machinery. It lowers profit but takes no cash out. At Pfizer Inc, in 2025: $6.59 bn · Δ −6.0% (2024).

$799.0 m-−8.9%$877.0 m-$525.0 m-$872.0 m-$1.18 bn-$756.0 m-

Shares given to employees instead of money. No cash cost, but it dilutes shareholders. At Pfizer Inc, in 2025: $799.0 m · Δ −8.9% (2024).

—-—-—-−$2.74 bn-−$7.31 bn-$2.89 bn-

Adjustments that bring accounting profit closer to money collected.

−$5.35 bn-−74.6%−$3.07 bn-−$2.17 bn-−$4.46 bn-$12.80 bn-−$275.0 m-

Money tied up in or released from inventory, receivables and payables. At Pfizer Inc, in 2025: −$5.35 bn · Δ −74.6% (2024).

of which: receivables−$263.0 m-−141%−$109.0 m-$347.0 m-$261.0 m-−$3.81 bn-−$1.25 bn-
of which: receivables, total—-—-—-$261.0 m-−$3.81 bn-−$1.25 bn-
of which: inventory$561.0 m-+166%−$854.0 m-$6.20 bn-$592.0 m-−$1.13 bn-−$736.0 m-
of which: liabilities—-—-—-−$803.0 m-$1.24 bn-$1.86 bn-
of which: other changes—-—-—-−$6.50 bn-$16.50 bn-$1.36 bn-
Other operating flows—-—-—-$26.90 bn-$21.40 bn-$6.87 bn-
Other non-cash items$4.85 bn-+146%$1.97 bn-$5.33 bn-$150.0 m-−$4.76 bn-$3.59 bn-
$11.71 bn-−8.2%$12.74 bn-$8.70 bn-$29.27 bn-$32.58 bn-$14.40 bn-

The money the business actually produced, before investment. At Pfizer Inc, in 2025: $11.71 bn · Δ −8.2% (2024).

$2.63 bn-−9.6%$2.91 bn-$3.91 bn-$3.24 bn-$2.71 bn-$2.79 bn-

Money put into factories, machinery and equipment. At Pfizer Inc, in 2025: $2.63 bn · Δ −9.6% (2024).

$1.73 bn-−34.8%$2.65 bn-−$32.28 bn-$11.13 bn-−$19.52 bn-−$2.59 bn-

Purchases and sales of financial holdings. At Pfizer Inc, in 2025: $1.73 bn · Δ −34.8% (2024).

Other investing flows$165.0 m-−97.0%$5.56 bn-−$180.0 m-−$12.55 bn-−$318.0 m-$573.0 m-
−$1.35 bn-−151%$2.65 bn-−$32.28 bn-−$15.78 bn-−$22.55 bn-−$4.27 bn-

The balance of investing cash. Negative means the company is building. At Pfizer Inc, in 2025: −$1.35 bn · Δ −151% (2024).

—-$0-$0-−$2.00 bn-$0-$425.0 m-

Shares bought back from the market or issued.

$9.77 bn-+2.7%$9.51 bn-$9.25 bn-$8.98 bn-$8.73 bn-$8.44 bn-

Money given to shareholders as dividends. At Pfizer Inc, in 2025: $9.77 bn · Δ +2.7% (2024).

−$74.0 m-+99.0%−$7.16 bn-$35.95 bn-−$3.52 bn-−$1.10 bn-−$12.76 bn-

Loans taken minus loans repaid. At Pfizer Inc, in 2025: −$74.0 m · Δ +99.0% (2024).

Other financing flows−$459.0 m-+2.1%−$469.0 m-−$632.0 m-$3.56 bn-$1.01 bn-$29.12 bn-
−$10.30 bn-+39.9%−$17.14 bn-$26.07 bn-−$14.83 bn-−$9.82 bn-−$9.65 bn-

The balance of financing cash: loans, dividends, buybacks. At Pfizer Inc, in 2025: −$10.30 bn · Δ +39.9% (2024).

$99.0 m-+105%−$1.81 bn-$2.45 bn-−$1.52 bn-$158.0 m-$475.0 m-

How much the cash in the bank rose or fell. At Pfizer Inc, in 2025: $99.0 m · Δ +105% (2024).

Change in cash and equivalents—-—-—-−$1.35 bn-$218.0 m-$483.0 m-
$1.04 bn-−64.2%$2.92 bn-$468.0 m-$1.98 bn-$1.83 bn-$1.35 bn-

Cash in the bank at the start of the period. At Pfizer Inc, in 2025: $1.04 bn · Δ −64.2% (2024).

$1.14 bn-+3.2%$1.11 bn-$2.92 bn-$468.0 m-$1.98 bn-$1.83 bn-

Cash in the bank at the end of the period. At Pfizer Inc, in 2025: $1.14 bn · Δ +3.2% (2024).

$9.08 bn-−7.7%$9.84 bn-$4.79 bn-$26.03 bn-$29.87 bn-$11.61 bn-

The money left after the business paid for its investments. Dividends and debt repayment come from here. At Pfizer Inc, in 2025: $9.08 bn · Δ −7.7% (2024).

from operations$2.62 bn+12.0%Q2 24Q1 26Q2 24−$1.78 bnQ3 24$6.71 bnQ4 24$6.72 bnQ1 25$2.34 bnQ2 25−$582.0 mQ3 25$4.60 bnQ4 25$5.35 bnQ1 26$2.62 bn
from investing$785.0 m−76.0%Q2 24Q1 26Q2 24$4.60 bnQ3 24−$2.06 bnQ4 24−$1.62 bnQ1 25$3.27 bnQ2 25$3.95 bnQ3 25−$2.43 bnQ4 25−$6.15 bnQ1 26$785.0 m
from financing−$2.86 bn+45.4%Q2 24Q1 26Q2 24−$2.46 bnQ3 24−$4.64 bnQ4 24−$5.11 bnQ1 25−$5.23 bnQ2 25−$3.20 bnQ3 25−$2.48 bnQ4 25$596.0 mQ1 26−$2.86 bn
Cash flows, quarterly, 6 periods
 Q1 26Δ Q1 25Q4 25Q3 25Q2 25Q1 25Q4 24
$2.70 bn-−9.3%−$1.65 bn-$3.55 bn-$2.93 bn-$2.97 bn-$411.0 m-

The profit left for shareholders after absolutely every expense. At Pfizer Inc, in Q1 26: $2.70 bn · Δ −9.3% (Q1 25).

$1.61 bn-−0.3%$1.69 bn-$1.66 bn-$1.63 bn-$1.62 bn-$1.79 bn-

The accounting wear on buildings and machinery. It lowers profit but takes no cash out. At Pfizer Inc, in Q1 26: $1.61 bn · Δ −0.3% (Q1 25).

$272.0 m-+60.0%$225.0 m-$201.0 m-$203.0 m-$170.0 m-$177.0 m-

Shares given to employees instead of money. No cash cost, but it dilutes shareholders. At Pfizer Inc, in Q1 26: $272.0 m · Δ +60.0% (Q1 25).

−$1.73 bn-+9.7%$1.59 bn-−$36.0 m-$1.92 bn-−$1.92 bn-$2.93 bn-

Money tied up in or released from inventory, receivables and payables. At Pfizer Inc, in Q1 26: −$1.73 bn · Δ +9.7% (Q1 25).

Other non-cash items−$222.0 m-−242%$4.15 bn-−$10.0 m-−$6.99 bn-$156.0 m-$1.81 bn-
$2.62 bn-+12.0%$5.35 bn-$4.60 bn-−$582.0 m-$2.34 bn-$6.72 bn-

The money the business actually produced, before investment. At Pfizer Inc, in Q1 26: $2.62 bn · Δ +12.0% (Q1 25).

$436.0 m-−22.7%$845.0 m-$602.0 m-$618.0 m-$564.0 m-$917.0 m-

Money put into factories, machinery and equipment. At Pfizer Inc, in Q1 26: $436.0 m · Δ −22.7% (Q1 25).

$1.20 bn-−63.4%$1.76 bn-−$2.43 bn-$3.95 bn-$3.27 bn-−$1.62 bn-

Purchases and sales of financial holdings. At Pfizer Inc, in Q1 26: $1.20 bn · Δ −63.4% (Q1 25).

Other investing flows−$770.0 m-−358%−$137.0 m-$12.0 m-−$9.0 m-$299.0 m-$12.0 m-
$785.0 m-−76.0%−$6.15 bn-−$2.43 bn-$3.95 bn-$3.27 bn-−$1.62 bn-

The balance of investing cash. Negative means the company is building. At Pfizer Inc, in Q1 26: $785.0 m · Δ −76.0% (Q1 25).

—-—-—-—-—-$0-

Shares bought back from the market or issued.

$2.45 bn-+0.3%$2.45 bn-$2.44 bn-$2.45 bn-$2.44 bn-$2.38 bn-

Money given to shareholders as dividends. At Pfizer Inc, in Q1 26: $2.45 bn · Δ +0.3% (Q1 25).

−$127.0 m-+94.8%$3.09 bn-$6.0 m-−$731.0 m-−$2.43 bn-−$2.72 bn-

Loans taken minus loans repaid. At Pfizer Inc, in Q1 26: −$127.0 m · Δ +94.8% (Q1 25).

Other financing flows−$284.0 m-+20.2%−$44.0 m-−$38.0 m-−$20.0 m-−$356.0 m-−$14.0 m-
−$2.86 bn-+45.4%$596.0 m-−$2.48 bn-−$3.20 bn-−$5.23 bn-−$5.11 bn-

The balance of financing cash: loans, dividends, buybacks. At Pfizer Inc, in Q1 26: −$2.86 bn · Δ +45.4% (Q1 25).

$563.0 m-+50.5%−$201.0 m-−$300.0 m-$213.0 m-$374.0 m-−$45.0 m-

How much the cash in the bank rose or fell. At Pfizer Inc, in Q1 26: $563.0 m · Δ +50.5% (Q1 25).

$1.20 bn-+8.1%$1.34 bn-$1.69 bn-$1.48 bn-$1.11 bn-$1.15 bn-

Cash in the bank at the start of the period. At Pfizer Inc, in Q1 26: $1.20 bn · Δ +8.1% (Q1 25).

$1.76 bn-+18.8%$1.14 bn-$1.39 bn-$1.69 bn-$1.48 bn-$1.11 bn-

Cash in the bank at the end of the period. At Pfizer Inc, in Q1 26: $1.76 bn · Δ +18.8% (Q1 25).

$2.18 bn-+23.0%$4.50 bn-$4.00 bn-−$1.20 bn-$1.77 bn-$5.80 bn-

The money left after the business paid for its investments. Dividends and debt repayment come from here. At Pfizer Inc, in Q1 26: $2.18 bn · Δ +23.0% (Q1 25).

earnings and surprises

88%Beat rate

Beats consistently

Next report

for Q2 26

Not yet announcedThe announced date, 29 July 2026, has passed. The company has not yet given the next one.

Earnings per share expected0.68between 0.61 and 0.76
Revenue expected$14.41 bn16 analysts
Last time−9.6%0.47 against 0.52 expected

What analysts expect from Pfizer Inc, further out

  • earnings per share estimated, fiscal year 2026 · 26 analysts2.96
  • earnings per share estimated, fiscal year 2027 · 26 analysts2.84

Pfizer Inc beat history

last 8 quarters

Beat rateBeat rateBeat rateBeat rateBeat rateBeat rateBeat rateAverage reaction when it misses

Of the last 8 quarterly reports from Pfizer Inc, 7 came in above analyst estimates and 1 below. The average surprise is +26.55%, and the latest was −9.62%, with earnings per share of 0.47 against 0.52 expected.

Beat rate88%surprise trend: slowing
Average reaction when it beats+0.5%of 7 beats, the price rose 3 times
Average reaction when it misses+0.6%

How the Pfizer Inc share price reacted

The move in Pfizer Inc shares on the day after each report. The middle line is zero.

reportresultnext day5 days
5 May 2026−−9.6%+0.57%5z −0.6%
3 February 2026++15.8%−3.34%5z +7.1%
4 November 2025++38.1%−1.46%5z +6.8%
5 August 2025++36.8%+5.18%5z −0.4%
29 April 2025++37.3%+3.21%5z −3.8%
4 February 2025++37.0%−1.26%5z −1.3%
29 October 2024+−1.39%5z −1.7%
30 July 2024++30.4%+2.18%5z −6.6%

The pattern shows: of those 7 beats, the price rose 3 times. The market does not react to the result, but to the difference from what was already in the price.

How the price moves around the reportover the last 8 reports
0.0%−1.8%+0.6%−1.1%
15 days beforereport day15 days after
Before the report
  • 5d before+0.6%rose 38% of the time
  • 10d before+1.6%rose 50% of the time
  • 21d before−1.3%rose 38% of the time
  • 42d before+1.1%rose 75% of the time
After the report
  • next day+0.6%rose 75% of the time
  • 5d after−0.1%rose 25% of the time
  • 10d after−0.4%rose 50% of the time
  • 15d after−0.2%rose 75% of the time
66% of the move, before34% at the announcement and after

The move is already in the price Of everything that moves the price around the report, 66% happens before the announcement. By the time the news is public, it is already in the quote.

A reliability of 38% means the pattern holds in fewer than half the cases: that is not a pattern, it is noise.

Everything is measured against the price on the report day, marked by the vertical line. Each half is the average of the trajectories from the quarters with enough price history, which is why the samples can differ.

What can go wrong

Risks & Resilience

Risks in Pfizer Inc (PFE) stock: balance sheet strength, distance from financial distress, and behaviour in past crises. The low-risk score is 67.0 out of 100, in the upper end of the market.

67.0 · solidLow risk

debt and solvency

81.9credit health

Nothing to fault

A balance sheet is judged on two things: whether the company can pay its debts out of what it produces, and how far it is from not being able to pay them at all. For Pfizer Inc, both answers are below.

Can it pay its debts?

Pfizer Inc: Yes, but without much room. Profit covers interest 2.56 times over, and debt stands at 3.98 times annual operating profit.

7581.9Credit health scoreComposite score summarising the firm's ability to carry its debt. Above 70 points to a solid balance sheet.
353.98xDebt / EBITDAHow many years of operating profit it would take to cover total debt. Below 3 is comfortable; above 4 becomes a burden.
1.532.56xInterest coverageHow many times operating profit covers the interest the company owes in a year. Above 3 is comfortable; below 1.5 means interest eats almost all the profit.
37.93Distance to default (Merton)How many standard deviations the firm value sits above its debt level. Above 3 is a comfortable margin.

How close is it to default?

Pfizer Inc: Very far. The composite score is 7.3 out of 100, on a scale where lower is better, and no model signals strain. Altman places it in the safe zone.

Altman Z'' scoreStatistical model estimating bankruptcy risk, adapted for non-financial firms. Above 2.6 is the safe zone; below 1.1 is the distress zone.
Probability of distress (Ohlson)Statistical model estimating the risk of financial distress. Low means a balance sheet under no strain.
Probability of distress (Zmijewski)Alternative model for estimating financial distress risk. Low means limited risk; useful as a cross-check on the Ohlson model.
Probability of default (Merton)Estimated chance the firm cannot service its debt over one year. Below 1% means negligible credit risk.

Forensic signals

8signals

Statistical models that look for patterns associated with aggressive reporting. Pfizer Inc: one signal to watch.

The quality of reported profit

Beneish M-scoreModel that detects patterns of aggressive accounting. Below −1.78 means no signals of aggressive reporting. A statistical test, not an accusation.
Montier C-score (0–6)Six warning signals about the quality of accounting. 0–1 is clean; 4 or above calls for caution.
Accruals ratio (Sloan)How much of reported profit is accounting only, rather than cash collected. Low or negative means profit is backed by real money.
Cash conversion rateHow much of accounting profit actually turns into cash. Above 100% means profit is more than covered by real money.
Stock-based compensation dilutionHow much of shareholders' stake is diluted by shares granted to employees. Below 2% a year is bearable dilution.
Goodwill shareHow much of the company’s assets are goodwill - the premium paid over book value in acquisitions. Above 30% of assets means a large part of the balance sheet depends on acquisitions working out.
Tax rate deviationHow far the tax actually paid differs from the statutory rate in the company’s country. Close to zero is normal. A large, sustained deviation is worth a look at the notes.

What the model raised

  • Montier C-scoreto watch

These are statistical screening models, not accusations. A signal means “worth a closer look”, not “this is fraud”. The Beneish, Montier, Sloan and Piotroski models are published in the academic literature; the thresholds used are those from the original papers.

A statistical screening signal, not an accusation of fraud.

Transparency · MAR

behaviour in a crisis

Held up better than its sectortwo crises measured

How Pfizer Inc shares behaved when the market fell. Not a forecast, but what happened in the crises the company has already been through.

How much of the market's fall it takes on

how much of the market's fall reaches the stock

absorbs part of it40%Takes on only 40% of the market's falls

the market 100%the stock 40%
  • Held up moderatelyHow well the company held up through economic contractions, against the rest of its sector.
  • Held up wellA composite score folding behaviour across every crisis measured, on a 0 to 100 scale.

What happened in past crises

how well it held up through the measured crises

83Held up very well

  • COVID-19 crash−29.3%2020 · above the sector median
  • 2022 bear market−30.2%2022 · above the sector median
  • Severe recession−18.2%A 2008-style economic contraction, with the market down about 40%
  • Interest rate shock−13.4%A sharp rise in interest rates
  • Market correction−9.1%A broad market decline of about 20%

Pfizer Inc: It held up better than the sector average in the measured crises, with a defensive profile.

Maximum drawdown is measured from peak to trough, on the actual price of that period. The scenarios are estimates, computed from historical sensitivity to the market.

Pfizer Inc (PFE) stock: biggest drops and how long the recovery took

The falls the price has been through, from a peak to the lowest point, and how long it took to recover.

Biggest drops since 2010

From a peak to the lowest point after it, how long the fall lasted and how long the recovery took.

  • Dec 2021 - Apr 2025-64.8%fell for 3 years and 4 months and has not got back to that peak: it has been below it for 4 years and 6 months
  • Nov 2018 - Mar 2020-38.4%fell for 16 months, then took 16 months to get back to the peak
  • Jan 2010 - Jul 2010-29.3%fell for 5 months, then took 9 months to get back to the peak

Measured on each day’s closing price, adjusted for splits, since 2010-01-04. Elsewhere on this page, drops are measured with dividends reinvested, which is why they can come out slightly smaller there.

What you get while you wait

Dividends and shareholder return

How much Pfizer Inc pays in dividends, how secure it is, and what happens to the share count.

dividends

6.12%Trailing yield

Pfizer Inc pays quarterly and has distributed $1.72 per share over the past twelve months, or 6.12% of today's price. The payout ratio is 225.88% of profit, meaning the dividend exceeds accounting profit for the period.

How much it pays and how secure it is

Trailing yieldDividends over the past twelve months, divided by today's price.
Forward yieldThe dividend announced for the coming year, divided by today's price.
Payout ratioHow much of profit goes out as dividend. A moderate figure leaves room to grow.
Dividend growth 5YAverage annual growth in dividend per share over five years.
Consecutive years of growthHow many years in a row the dividend per share has grown, without a single break.
Dividend safetyHow well the dividend is covered by profit and by cash.

Recent payments

  • Last dividend$0.43 · ex-date May 8, 2026
  • Frequencyquarterly
  • Payments in the last 12 months5
  • Dividends over 12 months$1.72
  • Cut risk73/100
ex-dateamountvs previous
May 8, 2026$0.43+0.0%
January 23, 2026$0.43+0.0%
November 7, 2025$0.43+0.0%
July 25, 2025$0.43+0.0%
May 9, 2025$0.43+0.0%
January 24, 2025$0.43+2.4%
November 8, 2024$0.42+0.0%
July 26, 2024$0.42—

Past returns do not necessarily repeat.

shareholder return

4.71%total return

Across dividends, buybacks and debt, Pfizer Inc returned 4.71% of its market value over the past twelve months.

6.70%from dividends
-1.53%from new debt
4.71%total return
  • 5Y allocation · dividends48.68%
  • 5Y allocation · buybacks2.11%

A negative total return means the company raised capital during the period, through borrowing or new shares, not that it took money from shareholders.

What you would have made

What has already happened, taken out of percentages and put into money.

What you would have made by investing in Pfizer Inc (PFE) stock

$1,000 put in Pfizer Inc stock 10 years ago, with dividends reinvested, would have grown to $1,311, a return of 2.74% a year. On the share price alone, without dividends, it would have been $765. Type your own amount and everything recalculates.

$
  • 3 years ago$870a loss of $130, at -4.55% a year
  • 5 years ago$893a loss of $107, at -2.23% a year
  • 10 years ago$1,311of which $311 is gain, at 2.74% a year

These figures have already happened and are not an estimate for what comes next. Dividends are reinvested in the same stock, and the amounts are in the currency the stock trades in, before tax and fees.

splits

5 events

Pfizer Inc has had 5 share events over the period covered by the data.

dateratiotype
November 17, 20201,054:1,000split
July 1, 19993:1split
July 1, 19972:1split
July 3, 19952:1split
April 1, 19912:1split

Amounts in the dividend history are adjusted for these events so they can be compared with each other. The sum actually received on the day was different.

Who owns it and what they do with it

Holders and flow

Who stands behind Pfizer Inc shares, what they buy and sell, and who bets against them.

institutional ownership

Pfizer Inc has 69.38% of its shares held by institutional investors. Of the 40 reported holders, 24 increased their position and 14 cut it.

Who holds how much

InstitutionsHow much of the stock is held by funds, banks and other professional investors.
Internal holdingsHow much is held by people and entities inside the company or close to it.
Largest holderHow much the single largest reported shareholder owns.
Top fiveHow much the five largest reported shareholders own together.
  • Reported holders40
  • Increased position24
  • Cut position14
  • Net share balance105.74M
  • As ofApril 30, 2026

Largest holders

Largest holders
holderstakechangeAs of
Vanguard Group Incpassive9.50%+1.32%12/31/2025
BlackRock Incpassive8.65%−0.88%12/31/2025
State Street Corppassive5.29%+0.38%03/31/2026
Vanguard Total Stock Mkt Idx Invpassive3.18%+0.30%04/30/2026
Vanguard 500 Index Investorpassive2.59%+1.83%04/30/2026
Geode Capital Management, LLC2.34%+2.59%03/31/2026
Fisher Asset Management, LLC1.84%+102.04%03/31/2026
Morgan Stanley - Brokerage Accounts1.63%+4.01%03/31/2026
iShares Core S&P 500 ETF1.29%+0.29%04/30/2026
NORGES BANK1.29%−21.48%12/31/2025
Fidelity 500 Index1.27%+0.35%03/31/2026
State Street® SPDR® S&P 500® ETF1.19%+0.33%04/30/2026
Northern Trust Corp1.09%−1.94%03/31/2026
Massachusetts Financial Services Company1.00%+1.86%03/31/2026
State Farm Mutual Automobile Ins Co0.96%+0.00%03/31/2026
Bank of New York Mellon Corp0.95%+11.06%03/31/2026
Vanguard Value Index Inv0.92%+0.30%04/30/2026
Charles Schwab Investment Management Inc0.91%+2.67%03/31/2026
Wellington Management Company LLP0.88%−4.18%03/31/2026
Bank of America Corp0.86%+9.83%12/31/2025
The Goldman Sachs Group Inc0.83%+17.60%03/31/2026
Amundi0.83%+13.43%12/31/2025
Legal & General Group PLC0.76%+1.50%03/31/2026
State Street®HlthCrSelSectSPDR®ETF0.72%−0.98%04/30/2026
Dimensional Fund Advisors, Inc.0.64%+0.81%03/31/2026
UBS Asset Mgmt Americas Inc0.61%−3.33%03/31/2026
Royal Bank of Canada0.60%−4.78%03/31/2026
Vanguard Institutional Index I0.55%−1.75%04/30/2026
State St S&P 500® Idx SL Cl I0.54%+0.99%04/30/2026
Vanguard Institutional 500 Index Trust0.45%−0.08%04/30/2026
Equity Index Fund E0.40%−0.80%12/31/2025
Equity Index Non-Lendable Fund B0.40%+0.00%12/31/2025
Equity Index Fund A0.40%−0.80%12/31/2025
Vanguard High Dividend Yield ETF0.39%+0.65%04/30/2026
Blackrock Eq Idx Fund CF0.36%−0.66%03/31/2026
Vanguard Equity-Income Inv0.34%−3.72%03/31/2026
iShares Select Dividend ETF0.33%+0.00%04/30/2026
Russell 1000 Index Fund0.32%−0.49%04/30/2026
Russell 1000 Index Non-Lendable Fund0.31%+0.82%12/31/2025
Russell 1000 Index Non-Lendable Fund B0.31%+0.00%12/31/2025
See all holders

The list covers only the largest reported holders, not the whole shareholder base. Stakes do not add up to 100%.

The holder type is noted only where the source states it.

congress

Over the past twelve months, members of the US Congress reported 2 purchases and 4 sales of Pfizer Inc shares.

What lawmakers traded

2purchases, 12 months4sales, 12 months
distinct buying members1
  • Purchases, 6 months0
  • Sales, 6 months0
  • Distinct selling members, 12 months3
  • As of03/13/2026

Who traded

Who traded
datenameside
03/13/2026Gilbert Ray Cisneros, Jr.sell
02/10/2026Gilbert Ray Cisneros, Jr.buy
01/22/2026Ro Khannasell
12/31/2025J. French Hillsell
12/19/2025Gilbert Ray Cisneros, Jr.sell
11/18/2025Gilbert Ray Cisneros, Jr.buy
09/15/2025Ro Khannasell
09/05/2025Ro Khannasell
08/05/2025Gilbert Ray Cisneros, Jr.sell
08/04/2025Ro Khannabuy
08/04/2025Lisa C. McClainsell
07/16/2025Lisa C. McClainbuy
07/01/2025Ro Khannabuy
06/20/2025Ro Khannabuy
06/03/2025Josh Gottheimersell
06/03/2025Ron Wydensell
05/30/2025Gilbert Ray Cisneros, Jr.buy
05/28/2025Ro Khannabuy
05/19/2025Ro Khannabuy
05/15/2025Robert Bresnahan, Jr.buy
See all transactions

The law requires reporting a value range, not the exact sum. That is why transactions are counted here rather than added up.

Transactions reported under the STOCK Act; informational.

short interest

Of Pfizer Inc freely tradable shares, 0.02% are sold short.

How much is sold short

Of free floatHow much of the freely tradable stock is sold short.
Days to coverHow many normal trading days it would take for short positions to be closed.
Shares shortThe number of shares sold short at the latest report.
  • Of total shares0.02%
  • Squeeze riskLow
  • As of05/27/2026

Short positions are reported twice a month, so the figure is older than the price on this page.

indices and ETFs

Pfizer Inc shares are held by 8 exchange-traded funds and belong to 1 indices.

Funds that hold it

Funds that hold it
fundsymbolweightassets
Health Care Select Sector SPDRXLV.US2.67%$39.24B
Vanguard High Dividend Yield ETFVYM.US63.00%$78.33B
Vanguard Value ETFVTV.US59.00%$179.59B
Vanguard S&P 500 ETFVOO.US25.00%$1.03T
iShares Core S&P 500 UCITSCSPX.LSE23.43%$146.69B
Vanguard Total Stock Market Index Fund ETF SharesVTI.US22.00%$653.54B
iShares Core MSCI World UCITSIWDA.LSE16.61%$101.7B
Vanguard Total World Stock ETFVT.US13.00%$74.09B
See all funds

Indices it belongs to

  • S&P 5000.23%

The weight is how much the share counts inside that fund, not how much of the company the fund owns.

Where it stands against the rest

Context & Comparisons

A number on its own says nothing. Here Pfizer Inc is placed next to its sector, its industry and the market, so every figure gets a position.

Position in sector

Healthcaresector

Pfizer Inc belongs to the Healthcare sector, in the Drug Manufacturers - General industry. Below, each indicator sits next to the sector and industry median.

Against sector and industry

indicatorcompanysector medianindustry medianposition
8.58%10.50%21.94%42
Return on equityHow much net profit the company generates from shareholders' money. Above ~15% is very good; consistency matters as much as the level.
3.55%4.44%9.21%43
Return on assetsHow much profit the company draws from the assets it owns. Above ~5% is solid, though it varies widely by industry.
6.77%8.66%17.72%42
Return on invested capitalProfit generated from all capital employed — equity and debt alike. Above the cost of capital (WACC) means value is created. Above 15% is very good.
11.83%8.18%17.70%61
Net margin (DuPont breakdown)The margin component of the DuPont breakdown of returns. Higher means the firm keeps more of every unit sold.
19.48x19.54x19.15x49
Price / earnings (trailing 12 months)How many years of current profit you pay for one share. Judged against sector and growth rate, never in isolation.
2.30x2.10x2.25x-
Price / sales (trailing 12 months)How many times annual sales you pay for a share. Useful for companies without profit; judged against the sector, not in absolute terms.
6.72%2.23%3.08%92
Dividend yield (trailing 12 months)Dividends paid over the past year against the current price. Judged together with sustainability, not on level alone.
130.54%33.17%50.71%-
Payout ratioHow much of the profit is paid out as dividend. Below 60% leaves room to grow; above 100% means the dividend exceeds the profit.
8.48%9.21%6.00%48
Revenue growth (5-year annual)Average yearly revenue growth over the past five years. Above ~10% is solid growth for a mature company.
-3.42%6.66%15.01%24
Earnings per share growth (5-year annual)Average yearly growth in earnings per share. Faster than revenue means expanding margins or buybacks.
3.98x1.46x1.49x14
Debt / EBITDAHow many years of operating profit it would take to cover total debt. Below 3 is comfortable; above 4 becomes a burden.
6.50%4.77%6.56%73
Free cash flow yieldHow much free cash the company produces relative to its market value. Above ~5% is attractive; below 2% is expensive.

Position is the percentile within the sector: 100 is the best value among the companies compared, 0 the weakest. The direction is already inverted where lower is better, as with debt or price/earnings.

Against the market

periodPFESPYdifference
1M-2.54%-0.08%−2.46%
3M-4.54%12.30%−16.84%
6M2.91%8.49%−5.58%
1Y16.80%24.76%−7.96%
3Y-20.13%80.71%−100.84%
5Y-16.91%88.11%−105.02%

Returns are cumulative over the period shown, not annualised. The difference is how much the company returned above or below the benchmark.

Transparency · MAR

Comparable companies

6comparable

Companies with a profile close to Pfizer Inc, chosen by how they move and what kind of stock they are - not by what they make.

The 6 closest

symbolcompanysimilarityscore
SNY.USSanofi ADRHealthcare87.5%41.1
Mercedes-Benz Group AGMBG.XETRAMercedes-Benz Group AGConsumer Cyclical86.2%49.7
UPS.USUnited Parcel Service IncIndustrials86.0%57.3
BASF SEBAS.XETRABASF SEBasic Materials86.0%42.6
VALE.USVale SA ADRBasic Materials85.8%59.2
FSUGY.USFortescue Metals Group Ltd ADRBasic Materials85.3%66.7

Similarity is computed from exposure to the same style factors, not from the line of business. That is why companies from other sectors can appear in the list. It is not a recommendation and not a list of alternatives.

Direct competitors

symbolcompanycountryscore
NONOF.USNovo Nordisk A/SUS65.5
NVO.USNovo Nordisk A/SUS44.9
GILD.USGilead Sciences IncUS64.7
AMGN.USAmgen IncUS49.6
BMY.USBristol-Myers Squibb CompanyUS49.9
SNY.USSanofi ADRUS41.1

Competitors from the same industry, Drug Manufacturers - General. The list is ordered by company size, but the figure is not shown: it comes in each market’s own currency, so the values are not comparable.

How the price moves

Market & Momentum

So far this has been about the company. From here on it is about the share: how much it swings, how deep it fell, and whether the move was worth the risk.

Volatility and risk

23.26%one-year volatility

How choppy Pfizer Inc has been, and how deep its falls have gone.

How much it swings

0.61calmer than the marketBetaHow strongly the share moves when the market moves. Below 1 is calmer than the market; above 1 amplifies its moves.
0.55Downside betaHow much the share moves against the market, measured ONLY on days the market falls. Lower than ordinary beta = falls less than it rises. Higher = amplifies the falls.
0.40Beta over the last yearThe same market sensitivity, but computed on the last twelve months only. Compared with long-term beta, it shows whether the share has turned choppier lately.
0.41Raw betaHow much the share moves against the market, without the usual statistical adjustment. Above 1 = moves more than the market. This is the unsmoothed figure; adjusted beta is steadier.
market
Annualised volatility (1 year)How much the price swings over a year, as a standard deviation. Lower means a smoother ride, not necessarily a higher return.
Annualised volatility (3 years)How widely the price swings in a year, measured over the last three. Below 20% is calm; above 40% takes a strong stomach.

How deep it fell

−58.96%Maximum drawdownThe largest peak-to-trough fall over the period analysed. Smaller is easier to sit through.
−46.95%Current drawdownHow far today’s price sits below the highest peak reached. Zero means it is at the peak. The deeper it is, the more there is to recover.
−3.10%Distance from the 52-week highHow far the price sits below its highest level of the past 52 weeks. Near zero = at the high. Deeply negative = it has given up a lot from the peak.
51.03%Likely worst-case drawdownHow deep the fall could be in the worst 5% of scenarios. Lower is better. It is a statistical estimate, not a guaranteed floor.
Ulcer index (1 year)How deep and how long the falls of the past year were, in a single figure. Lower is better: it measures discomfort, not just swing.
Ulcer index (3 years)How deep and how long the falls below previous peaks have been. Low means few long stretches spent below the peak.

Volatility and beta are computed from daily prices over the last year and the last three. They measure the past; they are not forecasts.

The words next to the figures are states with established names, not recommendations: “oversold” does not mean “worth buying”. Verdicts appear only on the risk ratios, where there is a clear direction of better.

Return against risk

0.55one-year Sharpe

The same gain earned with wide or narrow swings is not worth the same. The figures below divide the return by the risk it was earned with.

How much return for each unit of risk

0.55−0.41moderateSharpe ratioReturn above the risk-free rate for each unit of volatility. Above 1 is good; above 2 is remarkable.
0.86−0.57moderateSortino ratioLike Sharpe, but only penalising downward swings, not upward ones. Above 1.5 means good return relative to downside risk.
1.100.93goodOmega ratioThe ratio of gains to losses over the past year, weighted by their size. Above 1 means the good side weighed more than the bad.
0
Total return, 12 monthsGain over the past year, with dividends reinvested. Compared with the benchmark index, not in isolation.
Calmar ratioAnnual return divided by the largest drawdown suffered. Above 0.5 is decent. It says how much return you got for each unit of pain.
Treynor ratio (1 year)Return above the risk-free rate divided by beta - against market risk, not total swing. Higher is better. Useful when the share is held in a portfolio rather than alone.

All of them measure gain against some form of risk: Sharpe against total swing, Sortino against downward swing only, Calmar against the deepest fall, Treynor against market risk. Above 1 is generally good, but these compare between companies, not in absolute terms.

The words next to the figures are states with established names, not recommendations: “oversold” does not mean “worth buying”. Verdicts appear only on the risk ratios, where there is a clear direction of better.

Trend and oscillators

43.4814-day RSI

Where the Pfizer Inc share price sits against its moving averages, and how stretched the recent move is.

Against the averages

50-day moving averageThe average price over the last fifty trading sessions. It is the short-term reference: price above it means a recent upward trend.
200-day moving averageThe average price over the last two hundred sessions. It is the long-term reference, the most watched line in technical analysis.
yesAbove the 200-day averageWhether today’s price is above or below the long-term average. Above is read as a structural uptrend; below, a downtrend.
yesShort average above the long oneWhether the 50-day average is above the 200-day. When the short crosses above the long it is called a golden cross; the reverse, a death cross.
upMoving-average crossover stateWhich average is on top, expressed as +1 or −1. +1 = short above long; −1 = the reverse.
upParabolic SAR directionThe direction signal given by the Parabolic SAR indicator. +1 = uptrend; −1 = downtrend.

Oscillators

307043.48no signalRelative strength index (RSI 14)How fast the price rose or fell over the last fourteen days, on a scale from 0 to 100. Below 30 is considered oversold, above 70 overbought. In between, no signal.
-100100-66.36in the channelCommodity channel index (CCI 20)How far the price is from its twenty-day average, measured in typical deviations. Between −100 and +100 is normal; outside that, an unusual move against the recent pattern.
010.28in the bandPosition in the Bollinger bandWhere the price sits between the lower band (0) and the upper band (1) of the volatility channel. Below 0 or above 1 means the price has left the channel - rare, and usually brief.
202513.72no trendTrend strength (ADX 14)How clear the price direction is, whether it rises or falls. Above 25 = a clear trend; below 20 = it moves sideways.
MACD lineThe gap between the 12-day and the 26-day exponential average - how fast direction is changing. Above the signal and rising means upward momentum.
MACD signalThe nine-day average of the MACD line. It is the threshold the line is read against. It is not judged on its own: what matters is whether the line is above or below it.
MACD histogramThe gap between the MACD line and its signal - how fast momentum is changing. Positive and rising = upward momentum; negative = downward momentum.
On-balance volume slope (50 days)Where cumulative volume is heading over the last fifty sessions. Positive means more is being accumulated than distributed.

The thresholds marked on the scales are the usual ones in technical analysis: 30 and 70 for RSI, ±100 for CCI, 0 and 1 for the Bollinger band, 20 and 25 for trend strength. They are widely used conventions, not rules.

The words next to the figures are states with established names, not recommendations: “oversold” does not mean “worth buying”. Verdicts appear only on the risk ratios, where there is a clear direction of better.

Who it suits

15/30checks passed

Each row below is a way of investing. The more checks Pfizer Inc passes on one, the better it suits that way - there is no “correct” row.

StrongestDividends
WeakestMomentum and performance
  • passedUpside to fair valueHow much room there is between today’s price and the value computed from discounted cash flows. Positive means the model sees the share below its value.
  • passedPrice / earnings (trailing 12 months)How many years of current profit you pay for one share. Judged against sector and growth rate, never in isolation.
  • failedPrice / sales (trailing 12 months)How many times annual sales you pay for a share. Useful for companies without profit; judged against the sector, not in absolute terms.
  • passedFree cash flow yieldHow much free cash the company produces relative to its market value. Above ~5% is attractive; below 2% is expensive.
  • failedMargin of safetyHow far the market price sits below our fair-value estimate. Positive and wide means buying below value. Negative means paying above it.
  • passedReturn on capital above its costWhether the return on invested capital exceeds the weighted average cost of capital. Above the cost of capital the company creates value; below, it destroys it.
  • failedReturn on equityHow much net profit the company generates from shareholders' money. Above ~15% is very good; consistency matters as much as the level.
  • passedNet margin (DuPont breakdown)The margin component of the DuPont breakdown of returns. Higher means the firm keeps more of every unit sold.
  • failedCompetitive moatHow well defended the company’s position is against competitors. A wide moat means profit is harder to erode.
  • failedPiotroski F-scoreNine balance-sheet and profitability checks, one point for each one passed. Above 7 out of 9 is considered solid; below 3, weak.
  • passedSloan ratioHow much of the profit comes from accounting accruals rather than cash received. Near zero is better: the profit shows up in the account, not just the report.
  • passedWarning flagsThe number of forensic flags raised by the reporting-quality models. Zero is what you want to see.
  • failedDebt / EBITDAHow many years of operating profit it would take to cover total debt. Below 3 is comfortable; above 4 becomes a burden.
  • passedAltman Z'' scoreStatistical model estimating bankruptcy risk, adapted for non-financial firms. Above 2.6 is the safe zone; below 1.1 is the distress zone.
  • passedInterest coverageHow many times operating profit covers the interest the company owes in a year. Above 3 is comfortable; below 1.5 means interest eats almost all the profit.
  • passedProbability of default (Merton)Estimated chance the firm cannot service its debt over one year. Below 1% means negligible credit risk.
  • failedBehaviour in recessionHow the share behaved through recent economic contractions. A smaller fall than the market shows resilience.
  • failedEarnings per share growth (5-year annual)Average yearly growth in earnings per share. Faster than revenue means expanding margins or buybacks.
  • failedRevenue growth (5-year annual)Average yearly revenue growth over the past five years. Above ~10% is solid growth for a mature company.
  • failedRule of 40Revenue growth added to the profitability margin. Above 40 means a good balance between growth and profitability.
  • passedAnalyst revisionsWhich way analysts have moved their estimates lately. Upward means expectations are rising.
  • passedDividend yield (trailing 12 months)Dividends paid over the past year against the current price. Judged together with sustainability, not on level alone.
  • failedPayout ratioHow much of the profit is paid out as dividend. Below 60% leaves room to grow; above 100% means the dividend exceeds the profit.
  • passedStreak of good reportsHow many quarters in a row the company has beaten expectations. A long streak shows predictability; a broken one, a change.
  • passedTotal shareholder yieldDividends, buybacks and debt reduction taken together. The full picture of money returned to shareholders.
  • failedBeats, last yearHow many times over the last year the result came in above estimates. More beats suggest cautious estimates or good execution.
  • failedBeats, three yearsHow many times over the last three years the result came in above estimates. More beats suggest cautious estimates or good execution.
  • failedBeats, five yearsHow many times over the last five years the result came in above estimates. More beats suggest cautious estimates or good execution.
  • passedPrice momentumThe direction and strength of the recent price move. Positive means the recent trend is upward.
  • failedSharpe ratio (1 year)Return above the risk-free rate for each unit of volatility. Above 1 is good; above 2 is remarkable.

A failed check is not a flaw in itself: a growth company fails almost everything to do with value, and that is normal. What matters is the pattern, where it passes and where it fails, not the count on its own.

Transparency · MAR

Key figuresIndicatorsPros and consVerdict
AnalystsFair valueProjections
ProfitabilityGrowthEarnings qualityCapital efficiencyFinancial statementsEarnings reports
Debt and solvencyForensics and manipulationBehaviour in crisesBiggest drops
DividendsShareholder yieldWhat you would have madeSplits
Institutional holdingsCongressShort interestIndices and ETFs
Position in sectorComparable companiesWho it suits
Volatility and riskRisk-adjusted returnTrend and oscillators